WO2013127829A1 - Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs - Google Patents
Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs Download PDFInfo
- Publication number
- WO2013127829A1 WO2013127829A1 PCT/EP2013/053892 EP2013053892W WO2013127829A1 WO 2013127829 A1 WO2013127829 A1 WO 2013127829A1 EP 2013053892 W EP2013053892 W EP 2013053892W WO 2013127829 A1 WO2013127829 A1 WO 2013127829A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pro
- trp
- amino acid
- biradical
- resin
- Prior art date
Links
- 230000008499 blood brain barrier function Effects 0.000 title claims abstract description 56
- 210000001218 blood-brain barrier Anatomy 0.000 title claims abstract description 54
- 150000001875 compounds Chemical class 0.000 title claims description 79
- 108091005804 Peptidases Proteins 0.000 title description 6
- 239000004365 Protease Substances 0.000 title description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title description 2
- 150000001413 amino acids Chemical class 0.000 claims abstract description 127
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 86
- 238000010276 construction Methods 0.000 claims abstract description 37
- 150000003254 radicals Chemical class 0.000 claims abstract description 28
- 238000003745 diagnosis Methods 0.000 claims abstract description 19
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000002405 diagnostic procedure Methods 0.000 claims abstract description 11
- 239000003446 ligand Substances 0.000 claims abstract description 9
- 229940088623 biologically active substance Drugs 0.000 claims abstract description 8
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 5
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 116
- 238000011282 treatment Methods 0.000 claims description 111
- 239000000126 substance Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 19
- 239000002096 quantum dot Substances 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 16
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 16
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 claims description 13
- 239000002872 contrast media Substances 0.000 claims description 13
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 10
- 229960003638 dopamine Drugs 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 230000002555 anti-neurodegenerative effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- 229940124522 antiretrovirals Drugs 0.000 claims description 2
- 239000003903 antiretrovirus agent Substances 0.000 claims description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 238000009256 replacement therapy Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 29
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 abstract description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 471
- 239000011347 resin Substances 0.000 description 218
- 229920005989 resin Polymers 0.000 description 218
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 171
- 235000001014 amino acid Nutrition 0.000 description 113
- 229940024606 amino acid Drugs 0.000 description 111
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 108
- 238000005859 coupling reaction Methods 0.000 description 99
- 238000010168 coupling process Methods 0.000 description 90
- 230000008878 coupling Effects 0.000 description 89
- 239000000243 solution Substances 0.000 description 83
- 239000002904 solvent Substances 0.000 description 60
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 54
- 239000000047 product Substances 0.000 description 54
- 229910001868 water Inorganic materials 0.000 description 54
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 47
- 238000003756 stirring Methods 0.000 description 47
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 40
- 238000007398 colorimetric assay Methods 0.000 description 39
- 238000000034 method Methods 0.000 description 38
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 31
- 238000002360 preparation method Methods 0.000 description 28
- 150000003862 amino acid derivatives Chemical class 0.000 description 27
- -1 NalO4 Chemical compound 0.000 description 25
- 239000012317 TBTU Substances 0.000 description 23
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 23
- 238000003776 cleavage reaction Methods 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- 230000007017 scission Effects 0.000 description 23
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 20
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 19
- 238000012512 characterization method Methods 0.000 description 19
- 239000008363 phosphate buffer Substances 0.000 description 18
- 230000032258 transport Effects 0.000 description 18
- 239000003643 water by type Substances 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 16
- 238000004949 mass spectrometry Methods 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 229940043267 rhodamine b Drugs 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
- 238000004007 reversed phase HPLC Methods 0.000 description 13
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 150000008575 L-amino acids Chemical class 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 150000008574 D-amino acids Chemical class 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000002889 endothelial cell Anatomy 0.000 description 9
- 230000007717 exclusion Effects 0.000 description 9
- 239000007850 fluorescent dye Substances 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 8
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- 238000005804 alkylation reaction Methods 0.000 description 8
- 229910021538 borax Inorganic materials 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- 235000010339 sodium tetraborate Nutrition 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 7
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 7
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 7
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 7
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 7
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 6
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 150000003573 thiols Chemical class 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 5
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 229940031182 nanoparticles iron oxide Drugs 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- ZPGDWQNBZYOZTI-GOSISDBHSA-N (2r)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-GOSISDBHSA-N 0.000 description 4
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 4
- WOJKKJKETHYEAC-UHFFFAOYSA-N 6-Maleimidocaproic acid Chemical compound OC(=O)CCCCCN1C(=O)C=CC1=O WOJKKJKETHYEAC-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 229960000397 bevacizumab Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 229910052748 manganese Inorganic materials 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000004065 semiconductor Substances 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000007238 Transferrin Receptors Human genes 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 229940120638 avastin Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004088 microvessel Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000013930 proline Nutrition 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ADOHASQZJSJZBT-AREMUKBSSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-AREMUKBSSA-N 0.000 description 2
- UGNIYGNGCNXHTR-GOSISDBHSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-GOSISDBHSA-N 0.000 description 2
- ZZMSDLWVAMNVOD-JTQLQIEISA-N (2s)-1-phenylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C1=CC=CC=C1 ZZMSDLWVAMNVOD-JTQLQIEISA-N 0.000 description 2
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 description 2
- OJBNDXHENJDCBA-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 OJBNDXHENJDCBA-QFIPXVFZSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 2
- 229950004394 ditiocarb Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000011503 in vivo imaging Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L lucifer yellow dye Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
- 230000005381 magnetic domain Effects 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000031998 transcytosis Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000000733 zeta-potential measurement Methods 0.000 description 2
- XXMYDXUIZKNHDT-DIPNUNPCSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C(N=C1)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXMYDXUIZKNHDT-DIPNUNPCSA-N 0.000 description 1
- REITVGIIZHFVGU-LJQANCHMSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-LJQANCHMSA-N 0.000 description 1
- BUBGAUHBELNDEW-GOSISDBHSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-GOSISDBHSA-N 0.000 description 1
- UMRUUWFGLGNQLI-JOCHJYFZSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-JOCHJYFZSA-N 0.000 description 1
- QWXZOFZKSQXPDC-LLVKDONJSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-LLVKDONJSA-N 0.000 description 1
- HNICLNKVURBTKV-MUUNZHRXSA-N (2r)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-MUUNZHRXSA-N 0.000 description 1
- LZOLWEQBVPVDPR-VBKZILBWSA-N (2r,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H]([C@@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VBKZILBWSA-N 0.000 description 1
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 description 1
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 1
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 description 1
- GDPHPXYFLPDZGH-XBTMSFKCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 GDPHPXYFLPDZGH-XBTMSFKCSA-N 0.000 description 1
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 description 1
- KAADIULGJVQOCD-UHFFFAOYSA-N 1,1-bis(sulfanyl)ethyl carbamate Chemical compound CC(S)(S)OC(N)=O KAADIULGJVQOCD-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- 108700029992 Ala(2)-Arg(6)- enkephalin-Leu Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 241001501852 Diomedeidae Species 0.000 description 1
- FOQABOMYTOFLPZ-ISLYRVAYSA-N Disperse Red 1 Chemical compound C1=CC(N(CCO)CC)=CC=C1\N=N\C1=CC=C([N+]([O-])=O)C=C1 FOQABOMYTOFLPZ-ISLYRVAYSA-N 0.000 description 1
- 230000010777 Disulfide Reduction Effects 0.000 description 1
- CBPJQFCAFFNICX-LJQANCHMSA-N Fmoc-D-Leu-OH Chemical compound C1=CC=C2C(COC(=O)N[C@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-LJQANCHMSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GNJCUHZOSOYIEC-GAROZEBRSA-N Morphine-6-glucuronide Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)O)O[C@@H]1[C@]52CCN3C)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O GNJCUHZOSOYIEC-GAROZEBRSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WGNZRLMOMHJUSP-UHFFFAOYSA-N benzotriazol-1-yloxy(tripyrrolidin-1-yl)phosphanium Chemical compound C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 WGNZRLMOMHJUSP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000011198 co-culture assay Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000005293 ferrimagnetic effect Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000013149 parallel artificial membrane permeability assay Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000009057 passive transport Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010405 reoxidation reaction Methods 0.000 description 1
- 239000012508 resin bead Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000001650 transport into the brain Effects 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 238000005866 tritylation reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
Definitions
- the present invention relates to the fields of medicine, research and diagnostics, and more specifically to novel compounds that act as shuttles through the blood-brain barrier (BBB) for the delivery of substances that cannot cross the BBB by themselves. It also refers to shuttle-cargo constructs and their use in therapy or diagnostics. BACKGROUND ART
- neurodegenerative diseases such as Parkinson and Alzheimer diseases, but also central nervous system diseases such as schizophrenia, epilepsy or bipolar disorder, brain cancer, human immunodeficiency virus (HIV) and even certain aspects of obesity.
- central nervous system diseases such as schizophrenia, epilepsy or bipolar disorder, brain cancer, human immunodeficiency virus (HIV) and even certain aspects of obesity.
- the pharmaceutical targets of these diseases are located inside the brain.
- the BBB is a natural filter within the body that regulates the passage substances through from the blood to the brain, allowing only certain substances to cross from the blood to the brain. It is a natural defense mechanism designed to keep harmful substances out of the brain. It controls the composition of the brain extracellular fluid independent of fluctuations within the blood. It is also impermeable for many environmental compounds and drugs.
- the anatomical basis of the BBB is primarily the tight junction at endothelial cells of cerebral microvessels, which form a continuous membrane with no fenestrations.
- Specific transporters mediate the access of certain molecules important for the brain, such as glucose, isolated amino acids and ions.
- Other compounds can cross the BBB by a passive diffusion process through the endothelial cells that form the brain microvessels. However, this process requires a certain degree of lipophylicity of these compounds.
- This type of transport has the disadvantage of being very selective and to be regulated to some extent by efflux pumps, located in the membrane of endothelial cells that form the BBB, which prevent the accumulation of substances potentially toxic or unnecessary in the nervous system.
- efflux pumps located in the membrane of endothelial cells that form the BBB, which prevent the accumulation of substances potentially toxic or unnecessary in the nervous system.
- many promising compounds are known for their treatment, however, owing to their BBB transport problems, they are not further developed. Research in these fields has taken several
- Some methods of administration of drugs to the brain either for therapy or diagnosis are invasive techniques, such as intracranial administration, administration altering BBB integrity or osmotic disruption. However, these methods imply risk of infection and toxicity, and in addition, require qualified personnel.
- Another approach is the administration of the drug by conjugation to a biological carrier.
- This strategy is based on the conjugation of the drug to a substrate of a specific protein receptor or to an antibody that recognizes selectively a given receptor, e.g. the transferrin receptor or the receptor of LDL.
- This drug-carrier conjugate can be recognized by a particular receptor and undergoes a receptor-mediated endocytosis process into the nervous system, in such a way that compounds with a potential therapeutic use which cannot cross the BBB by themselves became able to cross this barrier when are conjugated with the carrier.
- Another approach comprises a peptide vector-mediated strategy in which non-transportable drugs are linked to peptides that have the capacity to cross the BBB (cf. J.Temsamani et al., "Improved Brain Uptake and
- WO2008025867 describes several compounds based on the structure of the diketopiperazine that act as vehicles for delivery active pharmaceutical ingredients through the BBB due to they have the capacity to carry drugs that lack capacity to pass the BBB, into the brain by passive diffusion.
- the permeability of the construct cargo-shuttle through the BBB was studied by means of the PAMPA assay, an in vitro model of the BBB.
- WO2012007625 describes the use of phenyl proline (PhPro) rich peptides as shuttles of compounds that are unable to cross the BBB.
- the described peptides can facilitate the transport of these compounds into the central nervous system.
- This patent application as WO2008025867, is based in the use of shuttles that are able to cross the BBB by a passive diffusion mechanism. This fact limits their use as shuttles to the transport of small molecules.
- WO200244329 describes a peptide, THRPPMWSPVWP (L-amino acids), which have the capacity to bind to the human transferrin receptor (hTfR) and internalized into cells expressing hTfR.
- This peptide can be link to other molecules, such as other peptides or proteins, in order to facilitate the transport of these molecules into cells expressing hTfR.
- the peptide and its ability to bind hTfR also described in Lee et al., in Eur J. Biochem. 2001 , vol. 268, p. 2004-2012.
- WO2007098415 describes that the peptide THRPPMWSPVWP (L-amino acids) can be used in vivo in order to direct macromolecules into cells expressing hTfR.
- PCNA proliferating cell nuclear antigen
- peptide THRPPMWSPVWP shows a low half-life time in human serum, thus, limiting their applications.
- WO2009008725 describes peptides or peptidomimetics comprising the sequence THRPPMWSPVWP (L-amino acids), as well as the conjugates that comprise these peptides and biological molecules or diagnostic, and their use to direct diagnostic biological molecules across the blood-brain barrier, brain cells, neuronal cells or tumor cells of neuroectodermal origin or neurons for the treatment of related disorders.
- the peptidomimetics described refers to variants of the above peptide comprising an amino acid substitution in the sequence for another amino acid or derivative of this one. Also describes that the peptide may consist entirely of L-amino acids or may contain one or more modifications in the backbone or side chains. All examples of the application refer to L-amino acids.
- the peptide PWVPSWMPPRHT D-amino acids
- the peptide GPWVPSWMPPRHT D-amino acids except the glycine that does not have chirality
- the peptides are biocompatible, have lack of toxicity and antigenicity as they are made of amino acids. Henceforth, these peptides will be referred as shuttle compounds.
- the mechanism of transport of the invention peptides across the BBB is by means of a receptor-mediated transcytosis through the transferrin receptor. This mechanism depends on the configuration L or D of the amino acids.
- the peptide compounds of this invention are also recognized by the hTfR receptor and have a surprising improved capacity to operate as shuttles respect to the peptide THRPPMWSPVWP (L-amino acids).
- the peptides have the capacity to internalize in brain endothelial cells and astrocytes. In addition to this have an improved apparent permeability across the BBB in comparison to the THRPPMWSPVWP sequence (L-amino acids).
- the peptide compounds of this invention also show a good solubility in water and a high stability in front of the proteases found in the blood. To be more precise, the peptides have large half-life times in human plasma, given that are resistant to the proteases found in this one. The peptides also show a high stability in front the peptidases associated with the brain microvessels. This property of the compounds of the invention allows improving the administration dose since the amount of solution containing the construct to be administered will be lower.
- a first aspect of the present invention refers to the provision of shuttle compounds of formula (I), or their pharmaceutically acceptable salts,
- the compounds of formula (I) are those
- the compounds of formula (I) or their salts may exist in solvated as well as unsolvated forms, including hydrated forms. Thus, in their structure may contain stoichiometric amounts of solvent in the case of solvates, or water in the case of hydrates. It should be understood that this invention
- the peptide compounds of formula (I) are those wherein P is a biradical consisting of SEQ ID NO: 1 and m is 0.
- the peptide compound of formula (I) are those wherein P is a biradical based in the sequence Gly-D-Pro-D-Trp-D-Val- D-Pro-D-Ser-D-Trp -D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 2) and m is 1 .
- compounds of formula (I) are those wherein Y is-NH 2 , -OH or -NHR 2 .
- compounds of formula (I) are those wherein Y is -NH 2 .
- the compounds of formula (I) are those where k is 0 or 1 .
- peptide compounds of formula (I) more preferred are those selected from the group consisting of:
- these peptides are referred as indicated above or as PWVPSWMPPRHT (D-amino acids) or GPWVPSWMPPRHT (D-amino acids), respectively.
- the compounds of formula (I) have the capacity to transport substances into the brain, referred as cargos, which cannot cross the BBB by themselves.
- another aspect of the invention relates to the use of these compounds of formula (I) as BBB-shuttles.
- the use of these compounds makes it possible for instance that the research of novel drugs is not only limited to the compounds that can cross the BBB by themselves.
- the compounds of formula (I) are better BBB shuttles than the closest prior art compounds.
- the compounds of formula (I) have appropriate functional groups suitable for covalent attachment of cargos maintaining the original activity of the cargo, until it reaches the site of action.
- Another aspect of the present invention is the provision of constructs of formula (II) or their pharmaceutically acceptable salts, which are referred as BBB shuttle-cargo constructs,
- X, P, Y, k are as defined above for the compounds of formula (I) and Z is a radical of a biologically active substance or a substance for use in a method of diagnosis, which is substantially unable to cross the BBB by itself.
- substantially unable to cross the BBB means that it is not capable of crossing the BBB, or if it does is in an amount that is therapeutically noneffective.
- Preferred values of X, P, Y, and k, for the compound of formula (I) are also preferred values for the construct of formula (II).
- the constructions of formula (II) are those where P is selected from the group consisting of a biradical of the sequence SEQ ID NO: 2 and a biradical of the sequence SEQ ID NO: 1 .
- constructions of formula (II) are those where k is an integer from 0 to 1 .
- the construction of formula (II) are those wherein Y is -NH 2 , -OH or -NHR 2 .
- Y is NH 2 .
- Y is -NHR 2, wherein R 2 is
- radical Z is derived from substances having pharmacological or diagnostic utility. These substances can be active pharmaceutical ingredients, in particular, antiretroviral agents, anticancer agents, anti-psychotic agents, antineurodegenerative agents or antiepileptic drugs.
- Z is a radical derived from an active pharmaceutical ingredient capable of forming an amide bond, an ester bond, a disulfide bond.
- Z is a radical derived from an active pharmaceutical ingredient capable of forming a thioeter bond, an oxime bond, an amine bond, or a hydrazone bond with X, the mentioned active ingredient being unable to cross the BBB by themselves.
- Example of active pharmaceutical ingredient is dopamine.
- Dopamine is a key neurotransmitter in the central nervous system; in particular, striatal dopamine depletion is associated with clinical conditions of Parkinsonism.
- Dopamine shown interesting properties as a drug but cannot cross the BBB.
- the constructs of formula (II) allow dopamine to be useful as a drug without having the undesired side effects of the actual therapy, and being a simpler and none invasive technique compared with the existing ones.
- peptides for example, peptides, proteins, polymers and antibodies, which have applications as therapeutic or diagnosis agents but that are unable to cross the BBB properly.
- the peptide is H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys (SEQ ID NO: 3). This peptide is useful for the treatment of Alzheimer's disease.
- antibodies are used as cargos.
- the antibody is bevacizumab (Avastin). This antibody is useful for the treatment of cancer.
- Substances derived from Z also include other substances that would be interesting to transport to the brain but they do not do it properly by
- contrast agents for magnetic resonance imaging MRI
- MRI magnetic resonance imaging
- contrast agents for magnetic resonance imaging
- MRI outstands as non-invasive and non-destructive powerful imaging modality that provides internal images of living organisms with no limits in the depth of analysis and with a resolution of 10 to 100 microns. It is a valuable technique widely used in cancer diagnosis and research.
- contrast agents For early detection of cancer (as well as other diseases) is interesting the use of contrast agents, which can be selectively directed to specific markers located in certain tissues, creating a small accumulation of contrast agent in this tissue. This small accumulation of contrast agent is enough to detect unequivocally the existence, for example, of a tumor in very early states.
- Contrast agents can also be used as diagnostic methods for other diseases of the central nervous system such as Alzheimer's disease, or as a tool for pre-operative MRI scan that will guide the surgeon. In all these cases the contrast agent used needs to cross the BBB.
- typical contrast agents includes include chelates of paramagnetic elements such as gadolinium or manganese (effect on T1 ), or the use of superparamagnetic nanoparticles of iron oxide (SPION nanoparticles) (T2 effect).
- Iron oxide nanoparticles are iron oxide particles with diameters between about 1 and 100 nanometers. The two main forms are magnetite (Fe 3 O 4 ) and its oxidized form maghemite (Y-Fe 2 O 3 ). They have attracted extensive interest due to their superparamagnetic properties and their potential applications in many fields (although Cu, Co and Ni are also highly magnetic materials, they are toxic and easily oxidized).
- Superparamagnetism is a form of magnetism, which appears in small ferromagnetic or ferrimagnetic micro or nanoparticles, every particle consisting of one magnetic domain.
- a magnetic domain is a region within a magnetic material which has uniform magnetization. This means that the individual magnetic moments of the atoms are aligned with one another and point in the same direction.
- Other no-MRI diagnostic agents include fluorescent dyes or probes such as carboxyfluorescein and its derivatives, rhodamine and its derivatives, or the use of quantum dots (nanoparticles formed by semiconductor materials with high fluorescence quantum yield).
- Quantum dots are semiconductors whose electronic characteristics are closely related to the size and shape of the individual crystal.
- the cargo Z includes antibodies useful in diagnostic methods.
- Carboxifluorescein as cargo or Z group Carboxifluorescein as cargo or Z group
- constructions of formula (II) are those selected from the group consisting of:
- Another aspect of the present invention relates to structures of formula (II) as defined above wherein Z is a radical of a biologically active substance being substantially unable to cross the BBB by itself, for use as a
- the substances with biological activity are selected from the substances with biological activity.
- Another aspect of the invention refers to structures of formula (II) where Z is a radical of dopamine for use in the treatment of Parkinson's disease. This can also be formulated as the use of constructs of formula (II) where Z is a radical of dopamine in the preparation of a medicament for the treatment of
- this aspect is related to a method of treatment and/or prophylaxis of a mammal, including a human, suffering from or being susceptible to develop Parkinson's disease, this method comprise the administration of a therapeutically effective amount of a compound of formula (II) with Z being a radical from dopamine, together with
- Another aspect of the invention relates to structures of formula (II) where Z is a peptide radical of the peptide H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D- Lys-D-Lys-NH 2 (SEQ ID NO: 3) for use in treatment of Alzheimer's disease.
- Z is a peptide radical of the peptide H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D- Lys-D-Lys-NH 2 (SEQ ID NO: 3) for use in treatment of Alzheimer's is described in
- WO2008050133 This aspect can also be formulated as the use of constructs of formula (II) where Z is a peptide radical of the peptide H-D-Ala-D-NMePhe- D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys-NH 2 (SEQ ID NO: 3) for the preparation of a medicament for the treatment of Alzheimer's disease.
- this aspect also relates to a method for the treatment and/or prophylaxis of a mammal, including a human, suffering from or being susceptible to develop Alzheimer's disease, this method comprise the administration of a therapeutically effective amount of a compound of formula (II) with Z being a peptide radical of the peptide H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys-NH2, together with pharmaceutically acceptable excipients or carriers.
- Another aspect of the invention relates to structures of formula (II) where Z is an antibody for use in treatment of cancer.
- Z is an antibody for use in treatment of cancer.
- the use of antibodies such as bevacizumab for the treatment of cancer is described in EP973804 but for the case of brain cancer (ex: glioblastoma) the transport of this antibody across the BBB is far from being optimal.
- This can also be formulated as the use of constructs of formula (II) where Z is an antibody for the preparation of a medicament for the treatment of cancer.
- this aspect also relates to a method for the treatment and/or prophylaxis of a mammal, including a human, suffering from or being susceptible to develop cancer, this method comprise the administration of a therapeutically effective amount of a compound of formula (II) with Z being an antibody, together with diluents, or pharmaceutically acceptable carriers.
- Another aspect of the invention relates to structures of formula (II) where Z is a superparamagnetic iron oxide nanoparticle (SPION nanoparticle), a gadolinium or manganese complex, for the use as contrast agent in a diagnostic method for magnetic resonance imaging.
- This technique is used for the localization and identification of malignant tumours, metastases of these ones or recurrences. It is also use for the diagnosis of Alzheimer's disease.
- This aspect can be also formulated as the use of a construction of formula (II) where Z is a superparamagnetic iron oxide nanoparticle (SPION nanoparticle), a gadolinium or manganese complex, for the preparation of a contrast agent for a method of magnetic resonance imaging.
- Z is a superparamagnetic iron oxide nanoparticle (SPION nanoparticle).
- SPION nanoparticle a superparamagnetic iron oxide nanoparticle
- Is also considered part of the invention a method for the diagnosis of a disease comprising administering to a mammal, including a human in need of such diagnostic a therapeutically effective amount of the construction of formula (II) wherein Z is an superparamagnetic iron oxide nanoparticle, a gadolinium or manganese complex, together with one or more
- the term "contrast agent” refers to agents that enhance the visibility of certain structures that are otherwise difficult to see during the scanning. These agents are used for injection into the vascular system to a local display.
- Another aspect of the invention relates to structures of formula (II) where Z is a radical of a fluorescent compound for use as a fluorescent probe in a method of imaging using two-photon microscopy, obtaining in vivo imaging of living organisms in a non-invasive way, serving as a diagnostic tool.
- This aspect can also be formulated as use of a construction of formula (II) where Z is a fluorescent compound for the preparation of a fluorescent probe for a method of imaging, for instance, using two-photon microscopy.
- suitable fluorescent compounds are 5(6)-carboxyfluorescein, Texas red, rhodamine or quantum dots.
- the fluorescent compound is 5(6)- carboxyfluorescein or quantum dots.
- the invention also relates to a method of diagnosis of a disease comprising administering to a mammal, including a human in need of such diagnostic a therapeutically effective amount of the construction of formula (II) where Z is 5(6)-carboxyfluorescein or a quantum dot together with one or more pharmaceutically acceptable excipients or carriers and / or acceptable for diagnosis, for generating an image using dual photon microscopy and diagnose using this image.
- the invention also relates to a method of diagnosis of a disease comprising administering to a mammal, including a human in need of such diagnostic a therapeutically effective amount of the construction of formula (II) where Z is an antibody with one or more pharmaceutically acceptable excipients or carriers and / or acceptable for diagnosis for a method of imaging.
- the peptide compounds of formula (I) and the constructions shuttle-cargo of formula (II) can be generated wholly or partly by chemical synthesis.
- the amino acids required for the preparation of compounds of formula (I) are commercially available.
- the compounds of formula (I) and construction of formula (II) can be prepared easily, for example by synthesis in liquid phase or, preferably, by solid-phase peptide synthesis, for which there are a number of procedures published (cf. M. Amblard, et al., "Methods and protocols of modern solid-phase peptide synthesis. Molecular Biotechnology 2006, Vol. 33, p. 239-254).
- the compounds of formula (I) or the constructions of formula (II) can also be prepared by any combination of liquid phase synthesis and/or solid phase synthesis. For example, by synthesizing the body of the shuttle through solid-phase synthesis and, subsequently removing protecting groups in solution.
- the binding of the cargo to the shuttle can be performed in solid phase or in solution. Particular shuttle and the binding to specific cargos are disclosed in more detailed in the examples.
- compositions comprising a therapeutically effective amount of the constructions shuttle- cargo of formula (II) as defined above where Z is a radical of a biologically active substance, together with appropriate amounts of pharmaceutically acceptable diluents or carriers.
- therapeutically effective amount refers to the amount of a compound that, when administered, is enough to prevent development of, or alleviate to some extent, one or more symptoms of the disease which is addressed.
- the particular dose of compound administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the compound administered, the via of administration, the particular condition being treated, and similar considerations.
- pharmaceutical composition refers to a mixture of a compound described herein with other chemical components, such as diluents or carriers.
- the pharmaceutical composition facilitates administration of the compound to an organism.
- pharmaceutically acceptable excipients or carriers refers to pharmaceutically acceptable material, composition or vehicle. Each component must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must be also suitable for use in contact with tissues or organs of humans and animals without excessive toxicity, irritation, allergic response,
- composition which comprises a construction according to the present invention may be administered alone or in combination with other treatments, either simultaneously or sequentially, depending on the condition to be treated.
- compositions with diagnostic purposes which have been called contrast agent or fluorescent probes depending on the construction radical Z of formula (II).
- These compositions comprise an effective amount of the constructions shuttle-cargo of formula (II) as defined above, where Z is a radical of a substance for use in a diagnostic method for MRI or two-photon spectroscopy, this substance being not able to cross the BBB by itself, together with appropriate amounts of
- diagnostic acceptable refers to those excipients or carriers suitable for use in diagnostic technology. They should not adversely affect the stability, safety or efficacy of the composition.
- pharmaceutically acceptable excipients or carriers and/or acceptable for diagnosis are physiologically acceptable sterile medium, i.e. isotonic aqueous solutions.
- compositions of the present invention may be administered in parenteral form suitable for injection, infusion or implantation into the body.
- a kit comprising the contrast agent according to the present invention in a container together with instructions for use in a diagnostic magnetic resonance imaging is provided.
- a kit comprising the fluorescent probe according to the present invention in a container together with instructions for use in a diagnostic method by two-photon microscopy is provided.
- PVDF Millipore polyvinylidine diFluoride
- Bevacizumab (Avastin ® )
- the test used for the identification and control of the synthesis was the following: A) Kaiser colorimetric assay for the detection of solid-phase bound primary amines (E. Kaiser et al., "Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides"; Anal. Biochem. 1970, vol. 34, pp. 595-598); The Kaiser test was performed by washing a small sample of resin (approx. 1 mg) in DMF (4 x 1 min) and DCM (4 x 1 min). Three drops of reagent A and six drops of reagent B were added to the resin, the resulting mixture was heated to 1 10 °C for 3 minutes. The presence of free primary amines beads is indicated by blue resin.
- Fmoc group removal Removal of the 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group was done with 20% (v/v) piperidine in DMF using 2 treatments of 1 0 minutes each. Two additional treatments with DBU, toluene, piperidine, DMF (5%, 5%, 20%, 70%) (2 x 5 min) were performed to ensure the removal of the Fmoc group from secondary amines (proline). Coupling methods:
- Coupling of the cargo in solid-phase Depending on the nature of the cargo, it will be linked to the BBB-shuttle through different types of chemical bonds.
- cargos with a COOH moiety e.g. L-dopa, 5(6)-carboxyfluorescein
- the coupling of the cargo onto the BBB-shuttle was done in solid-phase: the BBB- shuttle provided with a NH 2 group was used and was reacted with 4 eq of Cargo-COOH, using 4 eq of PyBOP and 12 eq of HOAt as coupling reagents and 12 eq of DIEA as a base in DMF during 2h.
- the mixture was allowed to react with intermittent manual stirring.
- the solvent was removed by suction, and the resin was washed with DMF (5 30 s) and DCM (5 30 s).
- the coupling was repeated two more times. The extent of coupling was checked by the p-nitro phenyl test.
- the coupling of the cargo with a COOH moiety was performed using the following protocol: 0.01 mmol (2 mg) of N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide and N-hydroxysuccinimide 0.025 mmol (3 mg) were added to 4 ml_ of a solution of quantum dots or to superparamagnetic iron oxide nanoparticles (2 mg) in MES (50 mM, pH 6.5), the mixture was allowed to react for 30 minutes and 0.08 pinoles of the shuttle were added (0.12 mg). The mixture was allowed to react for 24 h with gentle agitation. Excess peptide and unreacted reagent were removed by dialysis at 4 °C against water for 36 h. The water was changed every 12 hours.
- the coupling of antibody cargosi 0.01 mmol (2 mg) of N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide and N-hydroxysucc
- the linkage of the antibody to the BBB-shuttle could be done by one of the following technologies.
- the excipients are removed from the antibody formulation (i.e. bevacizumab (Bv) formulation) using size-exclusion chromatography followed by a concentration step using ultracentrifugal filtration to obtain a 20 mg/mL solution.
- This solution will be referred to as "BvW”.
- the antibody was concentrated to 100 ⁇ _ using a Vivaspin 500 with 50 kDa MWCO and washed twice with phosphate buffer 25 mM pH 6.2.
- the peptide bearing an aminooxy moiety 60 eq, 2.0- 10 "7 mol) was dissolved in 50 ⁇ _ of phosphate buffer 25 mM and the pH was made up to 6.2 with 1 M aqueous HCI.
- transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 ⁇ _ of a 4- 10 "3 M solution of aniline (60 eq, 2.0- 10 "7 mol, 1 .9- 10 "5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
- transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 ⁇ _ of a 4-10 "3 M solution of aniline (60 eq, 2.0- 10 "7 mol, 1 .9- 10 "5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
- 25 ⁇ _ of antibody solution (i.e BvW) (3.3- 10 "9 mol, 5.0- 10 "4 g) was diluted with 75 ⁇ _ of PBS pH 7.2 and incubated with 2-iminothiolane (30 eq, 1 .0- 10 "7 mol, 1 .4- 10 "5 g) for 1 h at 20°C.
- a Nap-5 size exclusion column was used to separate the non-reacted 2-iminothiolane from the thiolated antibody using PBS pH 7.2.
- the peptide bearing a maleimide moiety (10 eq, 3.3- 10 "8 mol) was dissolved in 50 ⁇ _ of PBS and mixed with the oxidized antibody. The mixture is left to react for 2 h at 20°C. Excess peptide is removed using a Nap-5 size-exclusion column using PBS pH 7.2.
- the antibody solution (i.e. BvW) was diluted (2 mgmL "1 , 500 ⁇ _) and was partially reduced by DTT (3.25 eq) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C.
- the excess of DTT was purified away from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following manufacturer instructions).
- the concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody. 4.1 .B. Reduction with TCEP
- the antibody solution i.e. BvW
- BvW The antibody solution
- TCEP 2.5 eq respectively
- TCEP 0.025 M sodium borate pH 8
- NaCI 0.025 M NaCI
- 1 mM EDTA 1 mM EDTA
- No purification was needed.
- the concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody.
- Partially reduced antibody was alkylated with 1 .1 molar equiv of 5(6)- carboxifluorescein-L-Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp- D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH 2 or rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH 2 /thiol.
- MALDI MALDI Voyager DE RP time-of-flight (TOF) PE Biosystem
- HPLC-MS Instrument: Waters model Alliance 2796, quaternary pump, UVA/is detector model 2487, ESI-MS model Micromass ZQ and software Masslynx version 4.0
- Symmetry 300 d 8 150 x 3.9 mm x 5 ⁇
- solvents A: H 2 O with 0.1 % formic acid
- B MeCN with 0.07 % formic acid.
- MALDI MALDI Voyager DE RP time-of-flight (TOF) PE Biosystem), SDS page.
- Fraction collector II controlled by the software Masslynx version 3.5.
- Example 1 Preparation of H-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D- Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 )
- the synthesis was performed on a scale 200 ⁇ .
- the protected derivative of the first amino acid (Fmoc-D- Thr(tBu)-OH, 4 eq, 800 pmols, 318 mg) and the coupling agent TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added
- the protected amino acid derivative of the second amino acid was coupled to the first amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-His(Trt)-OH, 4 eq. 800 mols, 496 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a solution of 20% piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the third amino acid was coupled to the second amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-D-Arg(Pbf)-OH, 4 eq. 800 mols, 519 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the fourth amino acid was coupled to the third amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ ). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colo metric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 1 0 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to ensure the removal of the Fmoc group.
- the protected amino acid derivative of the fifth amino acid was coupled to the fourth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), PyBOP (4 eq, 800 pmols, 41 6 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (1 2 eq, 2.4 mmol, 408 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the p-nitro phenyl ester colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 1 0 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 5 min) to ensure the removal of the Fmoc group.
- the protected amino acid derivative of the sixth amino acid was coupled to the fifth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Met-OH, 4 eq. 800 mols, 297 mg), PyBOP (4 eq, 800 pmols, 41 6 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (1 2 eq, 2.4 mmol, 408 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions.
- the extent of coupling was checked using the p-nitro phenyl ester the colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the seventh amino acid was coupled to the sixth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Trp(Boc)-OH, 4 eq. 800 mols, 421 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ _). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the eighth amino acid is coupled to the seventh amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Ser(tBu)-OH, 4 eq. 800 mols, 307 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ _). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino derivative of the ninth amino acid was coupled to the eighth amino already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to ensure the removal of the Fmoc group.
- the protected amino acid derivative of the tenth amino acid was coupled to the ninth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Val-OH, 4 eq. 800 mols, 271 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg), dissolved in DMF (1 -3 ml/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 ⁇ _). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric assay of p-nitro phenyl ester.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the eleventh amino acid was coupled to the tenth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Trp(Boc)-OH, 4 eq. 800 mols, 421 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ _). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the twelfth amino acid was coupled to the eleventh amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the extent of coupling was checked by the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to ensure the removal of the Fmoc group.
- the cleavage step was performed treating the resin with a mixture of TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h).
- tert-butyl methyl ether was added to the product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered and lyophilized.
- Example 2 Preparation of H-Glv-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D- Met-D-Pro-D-Pro-D-Arq-D -His-D-Thr-NH? (SEQ ID NO: 2) The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
- the coupling was repeated twice under the same conditions. The extent of coupling was monitored using the p-nitro phenyl ester test.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a treatment of 10 minutes.
- the cleavage step was performed treating the resin with a mixture of TFA
- Example 2 The procedure of the Example 2 was repeated until the coupling of the thirteenth amino acid using Hydroxylamine NovabiotagTM resin with a substitution of 0.56 mmol/g.
- the cleavage step was performed treating the resin with a mixture of TFA (95%), H 2 O (2.5%), and TIS (2.5%) (1 x 2 h).
- ferf-butyf methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H 2 O and MeCN (1 : 1 ). The product was filtered out and lyophilized.
- Reverse phase HPLC linear gradient from 1 7 to 23 % MeCN in H 2 O in 8 minutes using a Sunfire Ci 8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 6.4 min.
- Example 1 The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
- the following protocol was used: Fmoc-Lys(Boc -AoA)-OH (4 eq, 800 pmols, 513 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 ,uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and a treatment of 10 minutes.
- the cleavage step was performed treating the resin with a mixture of TFA (95%), H 2 O (2.5%), and TIS (2.5%) (1 x 2 h).
- TFA 95%
- H 2 O 2.5%
- TIS 2.5%)
- Terf-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H 2 O and MeCN (1 :1 ). The product was filtered out and lyophilized.
- Example 1 The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
- the cleavage step was performed treating the resin with a mixture of TFA (95%), H 2 0 (2.5%), and TIS (2.5%) (1 x 2 h).
- tert-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H 2 O and MeCN (1 :1 ). The product was filtered out and lyophilized.
- Example 1 The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
- the following protocol was used: Fmoc-Lys(alloc)-OH (4 eq, 800 pmols, 362 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and a treatment of 10 minutes.
- rhodamine b (4 eq, 800 pmols, 383 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HOAt (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 1 2 eq of DIEA (2.4 mmol, 408 ⁇ [_).
- the mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the coupling was repeated under the same conditions. The extent of coupling was monitored using the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a treatment of 10 minutes.
- the cleavage step was performed treating the resin with a mixture of TFA (95%), H 2 O (2.5%), and TIS (2.5%) (1 x 2 h).
- terf-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H 2 O and MeCN (1 : 1 ). The product was filtered out and lyophilized.
- Product characterization Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H 2 O in 8 minutes using a Sunfire Ci 8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 4.4 min.
- Mass spectrometry MALDI-TOF
- Example 7 Preparation of 5(6)-Carboxyfluorescein-L-Lvs(Maleimide)-D-Pro- D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D -His-D-Thr-NH? (SEQ ID NO:1 for the incorporation of two carqos)
- Example 1 The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
- the following protocol was used: Fmoc-Lys(alloc)-OH (4 eq, 800 pmols, 362 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 mols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and a treatment of 10 minutes.
- trityl chloride (12 eq, 2.4 mmol, 223 mg) was added to the resin. The mixture was allowed to react for 16 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the extent of coupling was monitored using the Kaiser colorimetric assay.
- the cleavage step was performed treating the resin with a mixture of TFA (95%), H 2 O (2.5%), and TIS (2.5%) (1 x 2 h).
- terf-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H 2 O and MeCN (1 :1 ). The product was filtered out and lyophilized.
- Example 8 Preparation of the compound L-dopa-D-Pro-D-Trp-D-Val-D-Pro- D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 with an L-dopa as cargo or Z group) The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
- the solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling was repeated twice under the same conditions. The extent of coupling was monitored using the p-nitro phenyl ester test.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the cleavage step was performed treating the resin with a mixture of TFA (94%), H 2 O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). Terf-butyl methyl ether and was added to product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
- the cleavage step was performed treating the resin with a mixture of TFA (94%), H 2 O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h).
- tert-butyl methyl ether was added to the obtained product, the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
- Example 2 The procedure was repeated as in Example 1 until the coupling of the twelfth amino acid.
- a molecule of glycine was used as a spacer between the shuttle and the cargo .
- Glycine was added to the shuttle anchored onto the resin using the following protocol: the protected amino acid (Fmoc-Gly-OH, 4 eq. 800 pmols, 190 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 ⁇ L).
- the mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric p- nitro phenyl ester assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the cleavage step of the shuttle with the spacer was performed treating the resin with a mixture of TFA (94%), H 2 O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h).
- the coupling of the shuttle equipped with the glycine spacer to the cargo was performed in solution according to the following protocol: 0.01 mmol (2 mg) of N-(3-dimethylaminopropyl)-N'-etilcarbodimida and 0.025 mmol of N-hydroxysuccinimide (3 mg) were added to 4 mL of a solution of quantum dots (2 mg) in MES (50 mM, pH 6.5), the mixture was allowed to react for 30 minutes. After which 0.08 ⁇ moles (0.12 mg) of the shuttle with spacer of glycine were added. This mixture was allowed to react for 24 h with gentle agitation.
- Example 1 1 Preparation of nanoparticle superparamagnetic iron oxide
- Example 10 was repeated until the cleavage step of the shuttle with the spacer inclusive.
- the binding of the shuttle with a glycine spacer to the superparamagnetic iron oxide nanoparticle in solution was performed according to the following protocol: 0.01 mmol (2 mg) of N-(3-dimethylaminopropyl)-N'-etilcarbodiimide and 0.025 mmoles of N-hydroxysuccinimide (3 mg) were added to 4 mL of a solution of nanoparticles (2 mg) in MES (50 mM, pH 6.5), allowed to react for 30 minutes and added 0.08 ⁇ (0.12 mg) of shuttle glycine spacer. It was allowed to react for 24 h under gentle agitation. Excess peptide and unreacted reagent was removed by dialysis at 4 ⁇ C against water for 36 h. The water was changed every 12 hours.
- the product was characterized by zeta potential measurements at pH 7.4. The product showed a post-shuttle potential of -31 mV Z (unbound nanoparticles to the shuttle showed a zeta potential of -37.1 mV).
- Example 12 Preparation of H-D-Ala-D-NMePhe-D-Nal(21-D-Val-D-Leu-D-Lvs- D-Lvs-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D ⁇ Arg-D- His-D-Thr-NH? jSEQ ID NO: 1 with SEQ ID NO: 3 as cargo or Z group)
- the cargo was synthesized by solid-phase synthesis directly on the shuttle anchored onto the resin.
- the first protected amino acid derivative of the cargo was coupled to the BBB-shuttle anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D- Lys(Boc)-OH, 4 eq. 800 pmols, 375 mg), PyBOP (4 eq, 800 umols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1-3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1.5 h.
- the solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the coupling reaction was repeated twice under the same conditions. The extent of coupling was checked using the colorimetric assay of p-nitro phenyl ester.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a 1 treatment of 10 minutes.
- the protected amino acid derivative of the second position of the cargo was coupled over the first amino acid of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Lys(8oc)-OH, 4 eq. 800 mols, 375 mg) and TBTU (4 eq, 800 ⁇ , 257 mg) dissolved in DMF (1-3 mL/g resin) were sequentially added to the resin, subsequently DIEA was added (8 eq, 1.3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the third position of the cargo was coupled to the second amino acid of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Leu-OH, 4 eq. 800 pmols, 283 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the position fourth of the cargo was coupled to the third amino acid position of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Val-OH, 4 eq. 800 pmols, 271 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the position of the fifth of the cargo was coupled to the fourth amino of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Nal(2)-OH, 4 eq. 800 pmols, 350 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 mL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the sixth position of the cargo was coupled to the fifth amino acid of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-NMePhe-OH, 4 eq. 800 pmols, 321 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the extent of coupling was checked by the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 5 min) to assess the removal of the Fmoc group.
- the protected amino acid derivative of the position of the seventh of the cargo was coupled to the sixth amino acid of the cargo anchored to the resin using the following protocol: the protected amino acid (Fmoc-D-Ala-OH, 4 eq.
- the cleavage step of the cargo-shuttle construction was performed treating the resin with a mixture of TFA (94%), H 2 O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). Te/t-butylmethyl ether was added to the product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
- Example 3 was repeated until the cleavage step.
- the binding of the shuttle with the antibody was done following aminooxy tech 1 , in solution was performed according to the following protocol: 25 ⁇ _ of BvW (3.3- 10 "9 mol, 5.0- 10 "4 g) was diluted with 75 ⁇ of phosphate buffer 25 mM pH 6.5.
- His-D-Thr-aminooxy 60 eq, 2.0- 10 "7 mol
- 50 ⁇ _ of phosphate buffer 25 mM 50 ⁇ _ of phosphate buffer 25 mM
- the pH was made up to 6.2 with 1 M aqueous HCI.
- the transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 ⁇ _ of a 4- 10 "3 M solution of aniline (60 eq, 2.0- 10 "7 mol, 1 .9- 10 "5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
- conjugates were characterized by MALDI-TOF MS and the amount of peptide was quantified using 3 cycles of Edman sequencing (1 -2
- Example 14 Preparation of H-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D- Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-Antibodv (SEQ ID NO: 2 with an antibody as cargo or Z group) using tech 2 Example 3 was repeated until the cleavage step.
- the binding of the shuttle with the antibody was done following aminooxy tech 2, in solution was performed according to the following protocol: 25 ⁇ _ of BvW (3.3- 10 "9 mol, 5.0- 10 "4 g) was diluted with 75 ⁇ _ of PBS pH 7.2 and mixed with 10 ⁇ _ of 0.1 M NalO 4 in water (54 eq, 1 .0- 10 "6 mol, 2.1 - 10 "4 g). The mixture was left to react 2h at 4°C preserved from light. A Nap-5 size exclusion column was used to separate the excess small molecules from the derivatized antibody using phosphate buffer 50 mM pH 6.2.
- transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 ⁇ _ of a 4-10 "3 M solution of aniline (60 eq, 2.0- 10 "7 mol, 1 .9- 10 "5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
- the conjugates were characterized by MALDI-TOF MS (1 -2 peptides/Ab).
- Example 15 Preparation of 5(6)-Carboxyfluorescein-L-Lvs(Antibodv)-D-Pro- D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH ? (SEQ ID NO: 1 with 5(6)-Carboxifluorescein and an antibody as cargos or Z groups in the compound of formula (ID) using tech 3
- Example 7 was repeated until the cleavage step.
- the binding of the shuttle with the antibody was done following maleimido tech 3, in solution was performed according to the following protocol: 25 ⁇ _ of BvW (3.3- 10 "9 mol,
- Example 16 Preparation of 5(6)-Carboxifluorescein-L-Lvs(Antibodv)-D-Pro- D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH ? (SEQ ID NO: 1 with 5(6)-Carboxifluorescein and an antibody as cargos or Z groups in the compound of formula (ID) using tech 4.1 .A and 4.3.
- Example 7 was repeated until the cleavage step.
- the binding of the shuttle to the antibody was done following maleimido technology tech 4.
- An antibody solution (1 mgmL "1 , 500 ⁇ _) was partially reduced by DTT (3.25 eq, 2.2 ⁇ _, 10 mM) or TCEP (2.75 eq, 1 .8 ⁇ _, 10 mM) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C.
- the excess of DTT was purified away from the partially reduced antibody by size exiusion (Nap 5, GE Healthcare following manufacturer instructions).
- the concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody.
- Partially reduced antibody was alkylated with 1 .1 molar equiv of 5(6)- carboxifluorescein-L-Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp- D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH 2 /antibody-cysteine thiol (4eq, 5.8 ⁇ _, 10 mgmL "1 DMSO) The alkylation reaction was performed at 0 °C for
- Example 17 Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH ? (SEQ ID NO: 1 with Rhodamine b and an antibody as cargos or Z groups in the compound of formula (ID) using tech 3.
- Example 6 was repeated until the cleavage step.
- the binding of the shuttle with the antibody was done following maleimido tech 3, in solution was performed according to the following protocol : 25 ⁇ _ of BvW (3.3- 10 "9 mol, 5.0- 10 "4 g) was diluted with 75 ⁇ _ of PBS pH 7.2 and incubated with 2- iminothiolane (30 eq, 1 .0- 10 "7 mol, 1 .4- 10 "5 g) for 1 h at 20°C.
- a Nap-5 size exclusion column was used to separate the non-reacted 2-iminothiolane from the thiolated antibody using PBS pH 7.2.
- rhodamine b-L-Lys(maleimide)-D- Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr- NH 2 (10 eq, 3.3- 10 "8 mol, 7.4- 10 "5 g) was dissolved in 50 ⁇ _ of PBS and mixed with the oxidized antibody. The mixture is left to react for 2 h at 20°C. Excess peptide is removed using a Nap-5 size-exclusion column using PBS pH 7.2.
- Example 18 Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH ? (SEQ ID NO: 1 with Rhodamine b and an antibody as cargos or Z groups in the compound of formula (ID) using tech 4.1 .A and 4.3.
- Example 6 was repeated until the cleavage step.
- the binding of the shuttle with the antibody was done following maleimido technology tech 4.
- An antibody solution (1 mgmL "1 , 500 ⁇ _) was partially reduced by DTT (3.25 eq, 2.2 ⁇ _, 10 mM) or TCEP (2.75 eq, 1 .8 ⁇ _, 10 mM) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C.
- the excess of DTT was purified away from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following manufacturer instructions).
- the concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody.
- Partially reduced antibody was alkylated with 1 .1 molar equiv rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH 2 /antibody-cysteine thiol (4eq, 5.8 ⁇ _, 10 mgmL
- Example 19 Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH ? (SEQ ID NO: 1 with Rhodamine b and an antibody as carqos or Z groups in the compound of formula (ID) using tech 4.1 .B and 4.3.
- Example 6 was repeated until the cleavage step.
- the binding of the shuttle with the antibody was done following maleimido technology tech 4.
- An antibody solution (1 mgmL "1 , 500 ⁇ ) was partially reduced by TCEP (2.75 eq, 1 .8 il, 10 mM) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C.
- the concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.5 to 4.0
- Partially reduced antibody was alkylated with 1 .1 molar equiv rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH 2 /antibody-cysteine thiol (4eq, 5.8 ⁇ , 10 mgmL "1 DMSO) The alkylation reaction was performed at 0 °C for 30 min.
- Cysteine (1 mM final) was used to quench any unreacted, excess of rhodamine b -L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH 2 .
- Example 20 Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D'Pro-D-Pro-D-Arq-D-His-D-Thr-NHg (SEQ ID NO: 1 with Rhodamine b and an antibody as cargos or Z groups in the compound of formula (II)) using tech 4,2 and 4.3.
- Example 6 was repeated until the cleavage step.
- the binding of the shuttle with the antibody was done following maleimido technology tech 4.
- the antibody was alkylated with 1.1 molar equiv rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-0-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D- Arg-D-His-D-Thr-NH 2 /antibody-cysteine thiol (9 eq. 18 ⁇ , 10 mgmL "1 DMSO) The alkylation reaction was performed at 0 e C for 30 min.
- Cysteine (1 mM final) was used to quench any unreacted, excess of rhodamine b -L- l_ys(maleimido)-D-Pro-D-Trp ⁇ D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D- Arg-D-His-D-Thr-NH2.
- the excess of peptide was removed from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following
- the antibody concentration was quantified using Nanodrop (coef ext molar - 222714 M “1 cm “1 ).
- the synthesis was performed in a scale 200 ⁇ mol.
- the first protected amino acid (Fmoc-L -Pro-OH, 4 eq. 800 pmols, 270 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 microL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to assess the removal of the Fmoc group.
- the protected amino acid derivative of the second amino acid was coupled to the first amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Trp(Boc)-OH, 4 eq. 800 mols, 421 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 ⁇ ). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric assay of p-nitro phenyl ester.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the third amino acid protected derivative was coupled to the second amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-L-Val-OH, 4 eq, 800 mols, 271 mg) and the coupling agent TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin followed by addition of DIEA (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the fourth amino acid was coupled to the third amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU ( 4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 1 0 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to assess the removal of the Fmoc group.
- the protected amino acid derivative of the fifth amino acid was coupled to the fourth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Ser(tBu)-OH, 4 eq.
- the protected amino acid derivative of the sixth amino acid was coupled to the fifth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Trp(Boc)-OH, 4 eq.
- the protected amino acid derivative of the seventh amino acid was coupled to the sixth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Met-OH, 4 eq. 800 pmols, 297 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ _). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the eighth amino acid is coupled to the seventh amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to assess the removal of the Fmoc group.
- the protected amino acid derivative of the ninth amino acid was coupled to the eighth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Pro-OH, 4 eq.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 5 min) to assess the removal of the Fmoc group.
- the protected amino acid derivative of the tenth amino acid was coupled to the ninth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Arg (Pbf)-OH, 4 eq. 800 mols, 519 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 microL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h.
- the solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).
- the coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric p-nitro phenyl ester assay.
- the Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the protected amino acid derivative of the eleventh amino acid was coupled to the tenth amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-L-His(Trt)-OH, 4 eq. 800 mols, 496 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a 1 treatment of 10 minutes.
- the protected amino acid derivative of the twelfth amino acid was coupled to the eleventh amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Thr (tBu)-OH, 4 eq. 800 mols, 257 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 ⁇ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
- the cleavage step was performed treating the resin with a mixture of TFA (94%), H 2 O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h).
- tert-butyl methyl ether was added to the product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
- Product characterization
- Reverse phase HPLC linear gradient from 0 to 100% MeCN in H 2 O in 8 minutes using a Sunfire d 8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Retention time: 4.95 min.
- Comparative Example 1 was repeated but using the corresponding D-amino acids instead of L-amino acids.
- Example 21 Evaluation of transport across the BBB using an in vitro cell assay
- the evaluation method chosen to test the compounds of formula (I) and (II) of the invention was a cell-based assay consisting of a co-culture of brain endothelial cells and astrocytes, which allows to evaluate or to predict the transport of compounds through the BBB.
- the co-culture method used was described by Gaillard and de Boer in 2008 (Gaillard, PJ et al. "2B-Trans technology: targeted drug delivery across the blood-brain barrier” Methods Mol Biol 2008, vol. 437 pp. 161 -175) and consists in seeding of rat astrocytes in one side of a polycarbonate filter (transwell) and the seeding of bovine brain endothelial cells on the other side of the filter.
- endothelial cells are able to reach the confluence mimicking the BBB.
- the system allows studying the transport of compounds that can cross the BBB by a passive transport mechanism and/or active. Is commonly used model for permeation studies and toxicity of compounds across the BBB.
- the co-culture assay was used to determine the capacity of the constructions cargo-shuttle to cross the BBB.
- the apparent permeability of the compounds was measured in triplicate at a concentration of 50 ⁇ M for Examples 1 , 2, 3, 4 and 7, and at a concentration of 0.75 nM (referred to the particle
- (dQ/dt) is the amount of compound present in the compartment acceptor function of time (nmol/s).
- A is the area of the filter(cm2) and CO is the initial concentration of the compound applied in the donor compartment (nmol/mL).
- Table 2 it can be observed how the use of the shuttle-cargo construct allows that cargos that do not cross themselves are able to do so by means of the BBB-shuttle. Being the shuttle of the example 1 notably more effective than the comparative example 1 with L-amino acids or than the comparative example 2 with D-amino acids.
- the retroenantio version with D-amino acids has a surprisingly high transport through the blood-brain barrier.
- Table 2 Apparent permeability (Papp) and percentage of transport after a 2 hours assay for Examples 1 1 , 2, 8, 9, 10, 1 1 , 12, 15, 16, 17, 18, and 20. As controls the comparative example 1 and 2 are shown.
- SPION superparamagnetic iron oxide nanoparticles
- permeability values depend highly on the cargo used. For a large cargo such as quantum dots or SPION values close to 0.1 X10-6 cm/s and are considered to be very good.
- Example 22 Stability of the shuttle in human serum
- One of the major advantage of the shuttles of this invention is that unlike the vast majority of peptides composed exclusively of L-amino acids (which are rapidly metabolized by a series of enzymes present in the serum of the blood, thus limiting their therapeutic effects), these are made with D-amino acids, thus are not recognized by the metabolic enzymes present in the serum, thereby increasing significantly their half-life in serum.
- examples 1 and 2 and the peptides presented in the comparative examples 1 and 2, these were incubated at a concentration of 150 ⁇ M in buffer HBSS at 37 °C in the presence of 90% human serum. At a range of times, 50 ⁇ _ aliquots were collected to which methanol was added in order to precipitate the serum proteins. The samples were centrifuged, filtered and analysed by HPLC to determine the degree of degradation of the BBB-shuttle In Table 3, it can be observed how the shuttles with D-amino acids show a dramatic increase of its half-life time in human serum, while the version with L-amino acids (Comparative Example 1 ) is rapidly degraded.
- example 1 and 2 are about shuttle-stable proteases that have a surprisingly high transport through the blood-brain barrier.
- Table 3 half-life time of the BBB-shuttle. Comparative Example 1 is shown as control. Reference Compound Half-life time in compound serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The peptides of formula (I) R1-(X)K-P-Y, where: R1 is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from H, CH3C(=O)-, and maleimide;X is a biradical selected from-NH-(CH2)r- C(=O)-, -C(=O)-(CH2)r-C(=O)-, -S(CH2)r-, -S-(CH2)r-C(=O)-, -O-(CH2)r-, -S-CH2-CH(NH2 )-C(=O)-, –O-(CH2)r-C(=O)-, -(CH2)r-C(=O)-, -NH-O-CH2-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-, -(CH2)r-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-, and –NH-(CH2)r-CH(NHC(=O)CH2NH2)-C(=O)-; r is 1-5; P is a biradical of an amino acid sequence comprising the sequence D-Pro-D-Trp- D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1); Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is selected from -NH2, -OH, -OR2and -NHR2; R2is a radical selected from (C1-C6)-alkyl and (CH2)2-NH-C(=O)-CH2-O-NH2; k is 0-2; m is 0-1; with the proviso that when the biradical X is –C(=O)(CH2)rC(=O)-, then R1 is H; when the N of the amino acid of the sequence P to which is attached the biradical X is a biradical -NH-, then m is 1, and when is a biradical -N-, then m is 0; and when R1 is maleimide then the biradical X is -C(=O)-(CH2)r-C(=O)-,-CH(NH2)-C(=O)-, -(CH2)r-C(=O)-, and -(CH2)r-C(=O)-NH-(CH2)r -CH(NH2)-C(=O)-. The peptides are useful as shuttles through the blood brain barrier (BBB). The constructions BBB-shuttle-cargo, being the cargo of a biologically active substance or for use in a diagnostic method, are useful in therapy and diagnosis.
Description
Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
The present invention relates to the fields of medicine, research and diagnostics, and more specifically to novel compounds that act as shuttles through the blood-brain barrier (BBB) for the delivery of substances that cannot cross the BBB by themselves. It also refers to shuttle-cargo constructs and their use in therapy or diagnostics. BACKGROUND ART
Several severe health disorders require treatment of the brain. This includes neurodegenerative diseases such as Parkinson and Alzheimer diseases, but also central nervous system diseases such as schizophrenia, epilepsy or bipolar disorder, brain cancer, human immunodeficiency virus (HIV) and even certain aspects of obesity. The pharmaceutical targets of these diseases are located inside the brain.
The BBB is a natural filter within the body that regulates the passage substances through from the blood to the brain, allowing only certain substances to cross from the blood to the brain. It is a natural defense mechanism designed to keep harmful substances out of the brain. It controls the composition of the brain extracellular fluid independent of fluctuations within the blood. It is also impermeable for many environmental compounds and drugs.
The anatomical basis of the BBB is primarily the tight junction at endothelial cells of cerebral microvessels, which form a continuous membrane with no fenestrations. Specific transporters mediate the access of certain molecules important for the brain, such as glucose, isolated amino acids and ions. Other compounds can cross the BBB by a passive diffusion process through the endothelial cells that form the brain microvessels. However, this process requires a certain degree of lipophylicity of these compounds. This type of transport has the disadvantage of being very selective and to be regulated to some extent by efflux pumps, located in the membrane of endothelial cells that form the BBB, which prevent the accumulation of substances potentially toxic or unnecessary in the nervous system.
In the therapeutic areas mentioned above, many promising compounds are known for their treatment, however, owing to their BBB transport problems, they are not further developed. Research in these fields has taken several approaches.
Some methods of administration of drugs to the brain either for therapy or diagnosis are invasive techniques, such as intracranial administration, administration altering BBB integrity or osmotic disruption. However, these methods imply risk of infection and toxicity, and in addition, require qualified personnel.
Another approach is drug modification. These modifications include for instance reduction of drug size or increase of drug lipophylicity, but it is not always possible to introduce such modifications. In the case of introducing an irreversible modification it is necessary that it doesn't alter the drug activity once it gets to the target site. In the case of a bioreversible modification, it is necessary to find an enzymatic or chemical process that will recover the active drug once the prodrug is inside the central nervous system.
Another approach is the administration of the drug by conjugation to a biological carrier. This strategy is based on the conjugation of the drug to a substrate of a specific protein receptor or to an antibody that recognizes selectively a given receptor, e.g. the transferrin receptor or the receptor of LDL. This drug-carrier conjugate can be recognized by a particular receptor and undergoes a receptor-mediated endocytosis process into the nervous system, in such a way that compounds with a potential therapeutic use which cannot cross the BBB by themselves became able to cross this barrier when are conjugated with the carrier.
Finally, another approach comprises a peptide vector-mediated strategy in which non-transportable drugs are linked to peptides that have the capacity to cross the BBB (cf. J.Temsamani et al., "Improved Brain Uptake and
Pharmacological Activity Profile of Morpholine-6-Glucuronide Using a Peptide Vector-Mediated Strategy" in J. Pharmacol. Exp. Ther. 2005 vol. 313, pp. 712- 719). This approach it has been use to improve the brain uptake of several drugs, such as doxorubicin, penicillin, enkephalin analog dalargin, paclitaxel
and morphine-6-glucuronide. In some cases, this conjugation even increased drug solubility and bypassed the P-glycoprotein expressed in the BBB.
WO2008025867 describes several compounds based on the structure of the diketopiperazine that act as vehicles for delivery active pharmaceutical ingredients through the BBB due to they have the capacity to carry drugs that lack capacity to pass the BBB, into the brain by passive diffusion. The permeability of the construct cargo-shuttle through the BBB was studied by means of the PAMPA assay, an in vitro model of the BBB.
Likewise, WO2012007625 describes the use of phenyl proline (PhPro) rich peptides as shuttles of compounds that are unable to cross the BBB. The described peptides can facilitate the transport of these compounds into the central nervous system. This patent application, as WO2008025867, is based in the use of shuttles that are able to cross the BBB by a passive diffusion mechanism. This fact limits their use as shuttles to the transport of small molecules.
Several peptides have been described whose mechanism of transport across the BBB is through an active transport process of receptor-mediated transcytosis.
WO200244329 describes a peptide, THRPPMWSPVWP (L-amino acids), which have the capacity to bind to the human transferrin receptor (hTfR) and internalized into cells expressing hTfR. This peptide can be link to other molecules, such as other peptides or proteins, in order to facilitate the transport of these molecules into cells expressing hTfR. The peptide and its ability to bind hTfR also described in Lee et al., in Eur J. Biochem. 2001 , vol. 268, p. 2004-2012.
WO2007098415 describes that the peptide THRPPMWSPVWP (L-amino acids) can be used in vivo in order to direct macromolecules into cells expressing hTfR. In particular it is indicated that enhances release of peptide derivatives that inhibit the interaction of proliferating cell nuclear antigen (PCNA) in a specific manner and thus reduce cellular proliferation of malignant cells that express an isoform cancer specific caPCNA.
Unfortunately, the peptide THRPPMWSPVWP (L-amino acids) shows a low half-life time in human serum, thus, limiting their applications.
Finally, WO2009008725 describes peptides or peptidomimetics comprising the sequence THRPPMWSPVWP (L-amino acids), as well as the conjugates that comprise these peptides and biological molecules or diagnostic, and their use to direct diagnostic biological molecules across the blood-brain barrier, brain cells, neuronal cells or tumor cells of neuroectodermal origin or neurons for the treatment of related disorders. The peptidomimetics described refers to variants of the above peptide comprising an amino acid substitution in the sequence for another amino acid or derivative of this one. Also describes that the peptide may consist entirely of L-amino acids or may contain one or more modifications in the backbone or side chains. All examples of the application refer to L-amino acids.
On basis of the existing results, it would be desirable to have a compound with the capacity to cross the BBB able to transport cargos across it in an efficient manner. Likewise, it would be interesting that these compounds had a high stability in physiological conditions in order to avoid side effects and improve its efficiency.
SUMMARY OF THE INVENTION
Inventors have found that the peptide PWVPSWMPPRHT (D-amino acids) and the peptide GPWVPSWMPPRHT (D-amino acids except the glycine that does not have chirality), have the capacity to cross the BBB and are able to facilitate the transport into the brain of drugs or other substances useful for diagnosis, referred to as "cargos", which cannot cross the BBB by
themselves. The peptides are biocompatible, have lack of toxicity and antigenicity as they are made of amino acids. Henceforth, these peptides will be referred as shuttle compounds.
The mechanism of transport of the invention peptides across the BBB is by means of a receptor-mediated transcytosis through the transferrin receptor. This mechanism depends on the configuration L or D of the amino acids. In contrast to it was expected, the peptide compounds of this invention are also recognized by the hTfR receptor and have a surprising improved capacity to
operate as shuttles respect to the peptide THRPPMWSPVWP (L-amino acids). The peptides have the capacity to internalize in brain endothelial cells and astrocytes. In addition to this have an improved apparent permeability across the BBB in comparison to the THRPPMWSPVWP sequence (L-amino acids).
The peptide compounds of this invention also show a good solubility in water and a high stability in front of the proteases found in the blood. To be more precise, the peptides have large half-life times in human plasma, given that are resistant to the proteases found in this one. The peptides also show a high stability in front the peptidases associated with the brain microvessels. This property of the compounds of the invention allows improving the administration dose since the amount of solution containing the construct to be administered will be lower.
Thus, a first aspect of the present invention refers to the provision of shuttle compounds of formula (I), or their pharmaceutically acceptable salts,
Rr(X)K-P-Y, (I), wherein: R-, is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from the group consisting of H, CH3C(=O)-, and maleimide; X is a biradical selected from the group consisting of -NH-(CH2)r.C(=O)-, -C(=O)-(CH2)r-C(=O)-, -S(CH2)r, -S- (CH2)r-C(=O)-, -O-(CH2)r, -S-CH2-CH(NH2)-C(=O)-, -O-(CH2)r-C(=O)-, -(CH2)r- C(=O)-, -NH-O-CH2-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-, -(CH2)r-C(=O)-NH- (CH2)r-CH(NH2)-C(=O)-, and -NH-(CH2)r-CH(NHC(=O)CH2NH2)-C(=O)-;
wherein the biradical X is attached to Ri and to the N of the sequence P as follows: Ri -NH-(CH2)r-C(=O)-N(H)m-, R C(=O)-(CH2)r-C(=O)-N(H)m-, R S- (CH2)r-N(H)m-, R S-(CH2)r-C(=O)-N(H)m-, R O-(CH2)r-N(H)m-, R S-CH2- CH(NH2)-C(=O)-N(H)m, R O-(CH2)r-C(=O)-N(H)m-, R (CH2)r-C(=O)- N(H)m, RrNH-O-CH2-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)- N(H)m, R (CH2)r-C(=O)-NH- (CH2)r-CH(NH2)-C(=O)-N(H)m, and RrNH-(CH2)r-CH(NHC(=O)CH2NH2)- C(=O)-N(H)m; r is an integer from 1 to 5; P is a biradical of an amino acid sequence comprising the sequence D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp- D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1 ); Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is
selected from the group consisting of -NH2, -OH, -OR2 and -NHR2; R2 is a radical selected from the group consisting of (CrC6)-alkyl and (CH2)2-NH- C(=O)-CH2-O-NH2; k is an integer from 0 to 2; m is an integer from 0 to 1 ; with the proviso that when the biradical X is -C(=O)(CH2)rC(=O)-, then Ri is H; with the proviso that when the N of the amino acid of the sequence P to which is attached the biradical X is a biradical -NH-, then m is 1 , and when is a biradical -N-, then m is 0; and with the proviso that when R-, is maleimide then the biradical X is -C(=O)-(CH2)r-C(=O)-, -CH(NH2)-C(=O)-, -(CH2)r-C(=O)-, and -(CH2)r-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-.
In a preferred embodiment, the compounds of formula (I) are those
where: Ri is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from the group consisting of H, and CH3C(=O)- ; X is a biradical selected from the group consisting of -NH-(CH2)r-C(=O)-, -C(=O)-(CH2)r-C(=O)-, S (CH2)r, -S-(CH2)r- C(=O)-, -O-(CH2)r, -S-CH2-CH(NH2)-C(=O)- and -O-(CH2)r-C(=O)-; wherein the biradical X is attached to Ri and to the N of the sequence P as follows: Ri -NH-(CH2)r-C(=O)-N(H)m-, R C(=O)-(CH2)r-C(=O)-N(H)m-, R S-(CH2)r-N(H)m-, RrS-(CH2)r-C(=O)-N(H)m-, RrO-(CH2)r-N(H)m-, R S-CH2-CH(NH2)-C(=O)- N(H)m, and R O-(CH2)rC(=O)-N(H)m-; r is an integer from 1 to 3; P is a biradical of an amino acid sequence comprising the sequence D-Pro-D-Trp- D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1 ); Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is selected from the group consisting of -NH2, -OH, -OR2 and -NHR2; R2 is a radical (CrC6)-alkyl; k is an integer from 0 to 2; m is an integer from 0 to 1 ; with the proviso that when the biradical X is
-C(=O)(CH2)rC(=O)-, then Ri is H and with the proviso that when the N of the amino acid of the sequence P to which is attached the biradical X is a biradical -NH-, then m is 1 , and when is a biradical -N-, then m is 0.
The compounds of formula (I) or their salts may exist in solvated as well as unsolvated forms, including hydrated forms. Thus, in their structure may contain stoichiometric amounts of solvent in the case of solvates, or water in the case of hydrates. It should be understood that this invention
encompasses all the solvated forms, as well as unsolvated. Obtaining solvates and hydrates depends on the solvent used and the crystallization conditions that can be determined by the person skilled in the art.
In a preferred embodiment, the peptide compounds of formula (I) are those wherein P is a biradical consisting of SEQ ID NO: 1 and m is 0. In another preferred embodiment, the peptide compound of formula (I) are those wherein P is a biradical based in the sequence Gly-D-Pro-D-Trp-D-Val- D-Pro-D-Ser-D-Trp -D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 2) and m is 1 . In a more preferred embodiment, compounds of formula (I) are those wherein Y is-NH2, -OH or -NHR2. In another even more preferred embodiment, compounds of formula (I) are those wherein Y is -NH2. In another preferred embodiment, compounds of formula (I) are those wherein Y is -NHR2, wherein R2 is (CH2)2-NH-C(=O)-CH2-O-NH2.
Preferably, the compounds of formula (I) are those where k is 0 or 1 .
The peptide compounds of formula (I) more preferred are those selected from the group consisting of:
H-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D- Thr-NH2; and
H-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D- His-D-Thr-NH2.
In the present document these peptides are referred as indicated above or as PWVPSWMPPRHT (D-amino acids) or GPWVPSWMPPRHT (D-amino acids), respectively.
As explained in Example 21 , the compounds of formula (I) have the capacity to transport substances into the brain, referred as cargos, which cannot cross the BBB by themselves. Thus, another aspect of the invention relates to the use of these compounds of formula (I) as BBB-shuttles. The use of these compounds makes it possible for instance that the research of novel drugs is not only limited to the compounds that can cross the BBB by themselves. As illustrated by the comparative examples, the compounds of formula (I) are
better BBB shuttles than the closest prior art compounds.
The compounds of formula (I) have appropriate functional groups suitable for covalent attachment of cargos maintaining the original activity of the cargo, until it reaches the site of action. Thus, another aspect of the present invention is the provision of constructs of formula (II) or their pharmaceutically acceptable salts, which are referred as BBB shuttle-cargo constructs,
(Z)q-(X)K-P-Y, (II) wherein: X, P, Y, k are as defined above; q is an integer from 1 to 2, and Z is a radical of a biologically active substance or a substance for use in a diagnostic method, said substance being substantially unable to cross the BBB by itself; wherein when q is 1 , then Z is attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and when q is 2, then one Z is attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and the other Z is attached to a nitrogen of the biradical X. In a preferred embodiment, in the constructs of formula (II) or their
pharmaceutically acceptable salts q is 1 , and have the following formula
Ζ-(Χ)κ-Ρ-Υ, (ΙΓ) where: X, P, Y, k are as defined above for the compounds of formula (I) and Z is a radical of a biologically active substance or a substance for use in a method of diagnosis, which is substantially unable to cross the BBB by itself.
The term "substantially unable to cross the BBB" means that it is not capable of crossing the BBB, or if it does is in an amount that is therapeutically noneffective.
Preferred values of X, P, Y, and k, for the compound of formula (I) are also preferred values for the construct of formula (II).
Thus, in a preferred embodiment, the constructions of formula (II) are those where P is selected from the group consisting of a biradical of the sequence
SEQ ID NO: 2 and a biradical of the sequence SEQ ID NO: 1 .
In another preferred embodiment, the constructions of formula (II) are those where k is an integer from 0 to 1 .
In another preferred embodiment the construction of formula (II) are those wherein Y is -NH2, -OH or -NHR2. In a more preferred embodiment, Y is NH2. In another preferred embodiment Y is -NHR2, wherein R2 is
(CH2)2-NH-C(=O)-CH2-O-NH2.
The substances from which radical Z is derived include a wide range of substances having pharmacological or diagnostic utility. These substances can be active pharmaceutical ingredients, in particular, antiretroviral agents, anticancer agents, anti-psychotic agents, antineurodegenerative agents or antiepileptic drugs. In a preferred embodiment, Z is a radical derived from an active pharmaceutical ingredient capable of forming an amide bond, an ester bond, a disulfide bond. Alternatively, Z is a radical derived from an active pharmaceutical ingredient capable of forming a thioeter bond, an oxime bond, an amine bond, or a hydrazone bond with X, the mentioned active ingredient being unable to cross the BBB by themselves.
Example of active pharmaceutical ingredient is dopamine. Dopamine is a key neurotransmitter in the central nervous system; in particular, striatal dopamine depletion is associated with clinical conditions of Parkinsonism. Dopamine shown interesting properties as a drug but cannot cross the BBB. In particular, as illustrated in the examples, the constructs of formula (II) allow dopamine to be useful as a drug without having the undesired side effects of the actual therapy, and being a simpler and none invasive technique compared with the existing ones.
Other possible cargos are, for example, peptides, proteins, polymers and antibodies, which have applications as therapeutic or diagnosis agents but that are unable to cross the BBB properly. In a particular embodiment, the peptide is H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys (SEQ ID NO: 3). This peptide is useful for the treatment of Alzheimer's disease. In a particular embodiment, antibodies are used as cargos. In a preferred embodiment the antibody is bevacizumab (Avastin). This antibody is useful
for the treatment of cancer.
Substances derived from Z also include other substances that would be interesting to transport to the brain but they do not do it properly by
themselves, for example contrast agents for magnetic resonance imaging (MRI). Among clinical devices used for clinical cancer diagnosis, MRI outstands as non-invasive and non-destructive powerful imaging modality that provides internal images of living organisms with no limits in the depth of analysis and with a resolution of 10 to 100 microns. It is a valuable technique widely used in cancer diagnosis and research. For early detection of cancer (as well as other diseases) is interesting the use of contrast agents, which can be selectively directed to specific markers located in certain tissues, creating a small accumulation of contrast agent in this tissue. This small accumulation of contrast agent is enough to detect unequivocally the existence, for example, of a tumor in very early states. Contrast agents can also be used as diagnostic methods for other diseases of the central nervous system such as Alzheimer's disease, or as a tool for pre-operative MRI scan that will guide the surgeon. In all these cases the contrast agent used needs to cross the BBB. Examples of typical contrast agents includes include chelates of paramagnetic elements such as gadolinium or manganese (effect on T1 ), or the use of superparamagnetic nanoparticles of iron oxide (SPION nanoparticles) (T2 effect). Iron oxide nanoparticles are iron oxide particles with diameters between about 1 and 100 nanometers. The two main forms are magnetite (Fe3O4) and its oxidized form maghemite (Y-Fe2O3). They have attracted extensive interest due to their superparamagnetic properties and their potential applications in many fields (although Cu, Co and Ni are also highly magnetic materials, they are toxic and easily oxidized).
Superparamagnetism is a form of magnetism, which appears in small ferromagnetic or ferrimagnetic micro or nanoparticles, every particle consisting of one magnetic domain. A magnetic domain is a region within a magnetic material which has uniform magnetization. This means that the individual magnetic moments of the atoms are aligned with one another and point in the same direction. Other no-MRI diagnostic agents include fluorescent dyes or probes such as carboxyfluorescein and its derivatives, rhodamine and its derivatives, or the use of quantum dots (nanoparticles formed by semiconductor materials with
high fluorescence quantum yield). The latter, combined with the use of two- photon microscopy, like in the MRI technique, allows in vivo imaging of living organisms in a no-invasive manner, thus allow their use as diagnostic tool. A quantum dot is a portion of matter (e.g., semiconductor) whose excitons are confined in all three spatial dimensions. Consequently, such materials have electronic properties intermediate between those of bulk semiconductors and those of discrete molecules. Quantum dots are semiconductors whose electronic characteristics are closely related to the size and shape of the individual crystal. Generally, the smaller the size of the crystal, the larger the band gap, the greater the difference in energy between the highest valence band and the lowest conduction band becomes, therefore more energy is needed to excite the dot, and concurrently, more energy is released when the crystal returns to its resting state.
Also in a preferred embodiment the cargo Z includes antibodies useful in diagnostic methods.
The more preferred constructions of formula (II) are those selected from the group consisting of:
L-Dopa-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D- His-D-Thr-NH2 ((lla); SEQ ID NO: 1 with an L-dopa as cargo or Z group); H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys- D-Pro-D-Trp-D-Val- D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 ((Mb); SEQ ID NO: 1 with SEQ ID NO:3 as cargo or Z group);
5(6)-Carboxifluorescein-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro- D-Pro-D-Arg-D-His-D-Thr-NH2 ((llc); SEQ ID NO: 1 with 5(6)-
Carboxifluorescein as cargo or Z group);
Quantum dot-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH2 ((lld); SEQ ID NO: 2 with Quantum dot as cargo or Z group); and
SPION-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-
Arg-D-His-D-Thr-NH2 ((lie); SEQ ID NO: 2 with SPION as cargo or Z group).
In a particular embodiment constructions of formula (II) are those selected from the group consisting of:
5(6)-Carboxifluorescein-L-Lys(Antibody)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D- Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 ((llf); SEQ ID NO: 1 with 5(6)— Carboxifluorescein and an antibody as cargos or Z groups); and Rhodamine b-L-Lys(Antibody)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met- D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 ((llg); SEQ ID NO: 1 with Rhodamine b and an antibody as cargos or Z groups).
As mentioned above according to the cargo of the constructions of formula (II), these will be useful in therapy or diagnosis.
Thus, another aspect of the present invention relates to structures of formula (II) as defined above wherein Z is a radical of a biologically active substance being substantially unable to cross the BBB by itself, for use as a
medicament. Preferably, the substances with biological activity are
pharmaceutical active ingredients, in particular selected from the group of active ingredients mentioned above.
Another aspect of the invention refers to structures of formula (II) where Z is a radical of dopamine for use in the treatment of Parkinson's disease. This can also be formulated as the use of constructs of formula (II) where Z is a radical of dopamine in the preparation of a medicament for the treatment of
Parkinson's disease. Therefore, this aspect is related to a method of treatment and/or prophylaxis of a mammal, including a human, suffering from or being susceptible to develop Parkinson's disease, this method comprise the administration of a therapeutically effective amount of a compound of formula (II) with Z being a radical from dopamine, together with
pharmaceutically acceptable excipients or carriers. Another aspect of the invention relates to structures of formula (II) where Z is a peptide radical of the peptide H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D- Lys-D-Lys-NH2 (SEQ ID NO: 3) for use in treatment of Alzheimer's disease.
The use of peptide H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys- NH2 (SEQ ID NO: 3) for the treatment of Alzheimer's is described in
WO2008050133. This aspect can also be formulated as the use of constructs of formula (II) where Z is a peptide radical of the peptide H-D-Ala-D-NMePhe- D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys-NH2 (SEQ ID NO: 3) for the preparation of a medicament for the treatment of Alzheimer's disease. Therefore, this aspect also relates to a method for the treatment and/or prophylaxis of a mammal, including a human, suffering from or being susceptible to develop Alzheimer's disease, this method comprise the administration of a therapeutically effective amount of a compound of formula (II) with Z being a peptide radical of the peptide H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys-NH2, together with pharmaceutically acceptable excipients or carriers.
Another aspect of the invention relates to structures of formula (II) where Z is an antibody for use in treatment of cancer. The use of antibodies such as bevacizumab for the treatment of cancer is described in EP973804 but for the case of brain cancer (ex: glioblastoma) the transport of this antibody across the BBB is far from being optimal. This can also be formulated as the use of constructs of formula (II) where Z is an antibody for the preparation of a medicament for the treatment of cancer. Therefore, this aspect also relates to a method for the treatment and/or prophylaxis of a mammal, including a human, suffering from or being susceptible to develop cancer, this method comprise the administration of a therapeutically effective amount of a compound of formula (II) with Z being an antibody, together with diluents, or pharmaceutically acceptable carriers.
Another aspect of the invention relates to structures of formula (II) where Z is a superparamagnetic iron oxide nanoparticle (SPION nanoparticle), a gadolinium or manganese complex, for the use as contrast agent in a diagnostic method for magnetic resonance imaging. This technique is used for the localization and identification of malignant tumours, metastases of these ones or recurrences. It is also use for the diagnosis of Alzheimer's disease. This aspect can be also formulated as the use of a construction of formula (II) where Z is a superparamagnetic iron oxide nanoparticle (SPION nanoparticle), a gadolinium or manganese complex, for the preparation of a contrast agent for a method of magnetic resonance imaging. Preferably, Z is a superparamagnetic iron oxide nanoparticle (SPION nanoparticle).
Is also considered part of the invention a method for the diagnosis of a disease comprising administering to a mammal, including a human in need of such diagnostic a therapeutically effective amount of the construction of formula (II) wherein Z is an superparamagnetic iron oxide nanoparticle, a gadolinium or manganese complex, together with one or more
pharmaceutically acceptable excipients or carriers and/or acceptable for diagnosis, to generate image by magnetic resonance imaging and make a diagnosis using this image.
The term "contrast agent" refers to agents that enhance the visibility of certain structures that are otherwise difficult to see during the scanning. These agents are used for injection into the vascular system to a local display. Another aspect of the invention relates to structures of formula (II) where Z is a radical of a fluorescent compound for use as a fluorescent probe in a method of imaging using two-photon microscopy, obtaining in vivo imaging of living organisms in a non-invasive way, serving as a diagnostic tool. This aspect can also be formulated as use of a construction of formula (II) where Z is a fluorescent compound for the preparation of a fluorescent probe for a method of imaging, for instance, using two-photon microscopy. Examples of suitable fluorescent compounds are 5(6)-carboxyfluorescein, Texas red, rhodamine or quantum dots. Preferably, the fluorescent compound is 5(6)- carboxyfluorescein or quantum dots.
The invention also relates to a method of diagnosis of a disease comprising administering to a mammal, including a human in need of such diagnostic a therapeutically effective amount of the construction of formula (II) where Z is 5(6)-carboxyfluorescein or a quantum dot together with one or more pharmaceutically acceptable excipients or carriers and / or acceptable for diagnosis, for generating an image using dual photon microscopy and diagnose using this image.
The invention also relates to a method of diagnosis of a disease comprising administering to a mammal, including a human in need of such diagnostic a therapeutically effective amount of the construction of formula (II) where Z is an antibody with one or more pharmaceutically acceptable excipients or
carriers and / or acceptable for diagnosis for a method of imaging.
The peptide compounds of formula (I) and the constructions shuttle-cargo of formula (II) can be generated wholly or partly by chemical synthesis. The amino acids required for the preparation of compounds of formula (I) are commercially available. The compounds of formula (I) and construction of formula (II) can be prepared easily, for example by synthesis in liquid phase or, preferably, by solid-phase peptide synthesis, for which there are a number of procedures published (cf. M. Amblard, et al., "Methods and protocols of modern solid-phase peptide synthesis. Molecular Biotechnology 2006, Vol. 33, p. 239-254). The compounds of formula (I) or the constructions of formula (II) can also be prepared by any combination of liquid phase synthesis and/or solid phase synthesis. For example, by synthesizing the body of the shuttle through solid-phase synthesis and, subsequently removing protecting groups in solution. The binding of the cargo to the shuttle can be performed in solid phase or in solution. Particular shuttle and the binding to specific cargos are disclosed in more detailed in the examples.
Another aspect of the invention relates to pharmaceutical compositions comprising a therapeutically effective amount of the constructions shuttle- cargo of formula (II) as defined above where Z is a radical of a biologically active substance, together with appropriate amounts of pharmaceutically acceptable diluents or carriers. The term "therapeutically effective amount" as used herein, refers to the amount of a compound that, when administered, is enough to prevent development of, or alleviate to some extent, one or more symptoms of the disease which is addressed. The particular dose of compound administered according to this invention will of course be determined by the particular circumstances surrounding the case, including the compound administered, the via of administration, the particular condition being treated, and similar considerations.
The term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components, such as diluents or carriers. The pharmaceutical composition facilitates administration of the compound to an organism.
The terms "pharmaceutically acceptable excipients or carriers" refers to pharmaceutically acceptable material, composition or vehicle. Each component must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the pharmaceutical composition. It must be also suitable for use in contact with tissues or organs of humans and animals without excessive toxicity, irritation, allergic response,
immunogenicity, or other problems or complications commensurate with a benefit/risk ratio.
A composition which comprises a construction according to the present invention may be administered alone or in combination with other treatments, either simultaneously or sequentially, depending on the condition to be treated.
Finally, also form part of the invention the compositions with diagnostic purposes, which have been called contrast agent or fluorescent probes depending on the construction radical Z of formula (II). These compositions comprise an effective amount of the constructions shuttle-cargo of formula (II) as defined above, where Z is a radical of a substance for use in a diagnostic method for MRI or two-photon spectroscopy, this substance being not able to cross the BBB by itself, together with appropriate amounts of
pharmaceutically acceptable excipients or carriers and/or acceptable for diagnosis.
The term "diagnostic acceptable" refers to those excipients or carriers suitable for use in diagnostic technology. They should not adversely affect the stability, safety or efficacy of the composition. Generally, the pharmaceutically acceptable excipients or carriers and/or acceptable for diagnosis are physiologically acceptable sterile medium, i.e. isotonic aqueous solutions.
The compositions of the present invention may be administered in parenteral form suitable for injection, infusion or implantation into the body. In an additional aspect of the invention a kit comprising the contrast agent according to the present invention in a container together with instructions for use in a diagnostic magnetic resonance imaging is provided.
In another aspect of the invention a kit comprising the fluorescent probe according to the present invention in a container together with instructions for use in a diagnostic method by two-photon microscopy is provided.
Throughout the description and claims the word "comprise" and variations of the word, are not intended to exclude other technical features, additives, components, or steps. Furthermore, the word "comprise" encompasses the case of "consisting of. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention. The following examples are provided by way of illustration, and they are not intended to be limiting of the present invention. Furthermore, the present invention covers all possible combinations of particular and preferred embodiments described herein.
EXAMPLES
Protected amino acids, handles and resins were supplied by: Luxembourg Industries (Tel-Aviv, Israel), Neosystem (Strasbourg, France), Calbiochem- Novabiochem AG (Laufelfingen, Switzerland), Bachem AG (Bubendorf, Switzerland) or Iris Biotech (Marktredwitz, Germany). Other reagents and solvents used are summarized in Table 1 .
Table 1 Commercials suppliers and reagents used. DCM passed through an AI2O3 column. DMF is stored on molecular sieves 4A and nitrogen is bubbled in order to eliminate volatile agents.
Commercial
Reagents and solvents
supplier
Albatros Chem. Inc. N-hydroxybenzotriazole (HOBt)
L-dopa, piperidine, a-ciano-4-hydroxicinnamic acid
Aldrich (ACH), DOWEX MR-3 Mixed Bed, dispers red I, 1 ,8- diazabicyclo-[5.4.0]-undec-7-ene (DBU), 3-(4,5-
Commercial
Reagents and solvents
supplier
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), triisopropylsilane (TIS), 1 ,2- ethanedithiol (EDT), borax, boric acid, 2-(N- morpholino)ethanesulfonic acid hydrate
(MES), N-Ethyl-N'-(3- dimethylaminopropyl)carbodiimide,
5(6)-carboxyfluorescein, HEPES, lucifer yellow, NaCI, KCI, CaCI2, MgCI2, NaHCO3, glucose, HBSS, pyridoxal 5'-phosphate, NalO4, 2-iminothiolane, tris(2- carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), tetrakis(triphenylphosphine)palladium(0), phenylsilane, rhodamine b, trytil chloride, sodium dithioethylcarbamate, 6-maleimidohexanoic acid
Applied GL
1 -hydroxy-7-azabenzotriazole (HOAt)
Biochem Shangai
Cell applications bovine brain endothelial cells
Charles river wistar rats
Corning Costar transwells (0.33 cm2; pore size 0.4 μιτι)
Jescuder NaOH
KaliChemie trifluoroacetic acid (TFA)
Lonza culture medium
molecular sieves 4A, Thin layer chromatography layers
Merck
(TLC)
superparamagnetic iron oxide nanoparticles (79-02-
Micromod
201 )
Millipore polyvinylidine diFluoride (PVDF) filters 0.45 μιτι
benzotriazol-1 -yl-oxytripyrrolidinophosphonium
Novabiochem hexafluorophosphate (PyBOP), N-hydroxisuccinimide
(NHS), hydroxylamine Novatag™ resin
dichloromethane (DCM), dimethylformamide (DMF),
Scharlau
MeOH, tert-butylmethylether
SDS acetone, MeCN, toluene
Thermo Scientific Slide-A-Lyzer MINI dialysis device floats
GE-Healthcare Nap-5 desalitng columns, Vivaspin 500 MWCO 50 kDa
Commercial
Reagents and solvents
supplier
Iris Biotech All amino acids except otherwise specified.
Vail d'Hebron
Bevacizumab (Avastin®)
Hospital Pharmacy
General considerations about the synthesis. Solid-phase peptide elongation and other solid-phase manipulations were carried out manually in
polypropylene syringes fitted with a polyethylene porous disk. Solvents and soluble reagents were removed by suction. Washings between different synthetical steps were carried out with dimethylformamide (DMF) (5 x 0.5 min) and dichloromethane (DCM) (5 x 0.5 min) using 10 ml_ of solvent/g of resin each time.
Identification tests. The test used for the identification and control of the synthesis was the following: A) Kaiser colorimetric assay for the detection of solid-phase bound primary amines (E. Kaiser et al., "Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides"; Anal. Biochem. 1970, vol. 34, pp. 595-598); The Kaiser test was performed by washing a small sample of resin (approx. 1 mg) in DMF (4 x 1 min) and DCM (4 x 1 min). Three drops of reagent A and six drops of reagent B were added to the resin, the resulting mixture was heated to 1 10 °C for 3 minutes. The presence of free primary amines beads is indicated by blue resin. B) p-nitro phenyl ester test for secondary amines bound to solid-phase (A. Madder et al., "A novel sensitive colorimetric assay for visual detection of solid-phase bound amines". Eur. J. Org. Chem. 1999, pp. 2787-2791 ). The p-nitro phenyl ester assay is performed by first washing a small sample of the resin (approx. 1 mg) with DMF (4x1 minutes) and DCM (4x1 minutes). To the resin ten drops of reagent solution (0.002 M p-nitrophenyl ester of disperse red 1 in MeCN) are added and the resulting mixture is heated at 70 °C for 10 minutes. The solution is then decanted and the resin washed with DMF until a transparent supernatant is obtained. The presence of secondary amines is indicated by red colored resin beads.
Protocols used during the synthesis of the constructs of formula (I) and (II).
the constructs were synthesized at a 200 μηηοΙ scale using the following methods and protocols:
Resin initial conditioning. The Fmoc-Rink amide p-MBHA resin was
conditioned by washing with DCM (5 30 s) and DMF (5 30 s) followed by a 20% piperidine solution in DMF (2 χ 1 min and 1 x 1 0 min) to remove the Fmoc group. Finally, the resin was washed with DMF (5 χ 30 s).
Fmoc group removal. Removal of the 9-fluorenylmethyloxycarbonyl (Fmoc) protecting group was done with 20% (v/v) piperidine in DMF using 2 treatments of 1 0 minutes each. Two additional treatments with DBU, toluene, piperidine, DMF (5%, 5%, 20%, 70%) (2 x 5 min) were performed to ensure the removal of the Fmoc group from secondary amines (proline). Coupling methods:
Coupling of the first amino acid onto the Rink amide p-MBHA resin: N- Protected amino acid (4 eq) and TBTU (4 eq) were added sequentially to the resin in DMF followed by DIEA (8 eq). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction; the resin was washed with DMF (5 χ 30 s) and DCM (5 χ 30 s). The extent of coupling was checked by the Kaiser colorimetric assay.
Coupling of second amino acid and the following amino acids onto the Rink amide p-MBHA resin: The procedure was the same as for the first one, except that the couplings over proline were done using 4 eq of N-protected amino acid, 4 eq of PyBOP, 1 2 eq of HOAt and 1 2 eq of DIEA, the reaction was carried out in DMF and the mixture was allowed to react with intermittent manual stirring (3 x 1 .5 h). The removal of the Fmoc group of the prolines, as well as the extend of the coupling was checked by the p-nitro phenyl ester test.
Coupling of the cargo (Z): Depending on the nature of the cargo, it will be linked to the BBB-shuttle in solid-phase or in solution.
Coupling of the cargo in solid-phase: Depending on the nature of the cargo, it will be linked to the BBB-shuttle through different types of chemical bonds.
For cargos with a COOH moiety (e.g. L-dopa, 5(6)-carboxyfluorescein) the coupling of the cargo onto the BBB-shuttle was done in solid-phase: the BBB- shuttle provided with a NH2 group was used and was reacted with 4 eq of Cargo-COOH, using 4 eq of PyBOP and 12 eq of HOAt as coupling reagents and 12 eq of DIEA as a base in DMF during 2h. The mixture was allowed to react with intermittent manual stirring. The solvent was removed by suction, and the resin was washed with DMF (5 30 s) and DCM (5 30 s). The coupling was repeated two more times. The extent of coupling was checked by the p-nitro phenyl test.
Final cleavage step:
It was carried out by treating resin with TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (2.5%) (1 x 1 h). Terf-butyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was discarded and the pellet was resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Coupling of the cargo in solution:
Cleavage step from the resin:
It was carried out by treating resin with TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (2.5%) (1 x 1 h). Tert-butyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was discarded and the pellet was resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
The coupling of the cargo with a COOH moiety (e.g. quantum dots, superparamagnetic iron oxide nanoparticles) in solution was performed using the following protocol: 0.01 mmol (2 mg) of N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide and N-hydroxysuccinimide 0.025 mmol (3 mg) were added to 4 ml_ of a solution of quantum dots or to superparamagnetic iron oxide nanoparticles (2 mg) in MES (50 mM, pH 6.5), the mixture was allowed to react for 30 minutes and 0.08 pinoles of the shuttle were added (0.12 mg). The mixture was allowed to react for 24 h with gentle agitation. Excess peptide and unreacted reagent were removed by dialysis at 4 °C against water for 36 h. The water was changed every 12 hours.
The coupling of antibody cargosi
The linkage of the antibody to the BBB-shuttle could be done by one of the following technologies.
In all cases, the excipients are removed from the antibody formulation (i.e. bevacizumab (Bv) formulation) using size-exclusion chromatography followed by a concentration step using ultracentrifugal filtration to obtain a 20 mg/mL solution. This solution will be referred to as "BvW".
Tech 1 - Conjugation at the N-termini
25 μΙ_ of antibody solution (i.e BvW) (3.3- 10"9 mol, 5.0- 10"4 g) was diluted with 75 μΙ_ of phosphate buffer 25 mM pH 6.5. Pyridoxal 5'-phosphate (PLP) (298 eq, 1 .0- 10"7 mol, 2.5- 10"5 g) was dissolved in 100 μΙ_ of phosphate buffer 25 mM and the pH was made up to 6.5 with 1 M HCI. The BvW solution was mixed with the PLP solution and incubated at 20 °C for 48 h. A Nap-5 size exclusion column was used to separate the excess small molecules from the derivatized antibody using phosphate buffer 25 mM pH 6.2. The antibody was concentrated to 100 μΙ_ using a Vivaspin 500 with 50 kDa MWCO and washed twice with phosphate buffer 25 mM pH 6.2. The peptide bearing an aminooxy moiety (60 eq, 2.0- 10"7 mol) was dissolved in 50 μΙ_ of phosphate buffer 25 mM and the pH was made up to 6.2 with 1 M aqueous HCI. The
transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 μΙ_ of a 4- 10"3 M solution of aniline (60 eq, 2.0- 10"7 mol, 1 .9- 10"5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
Tech 2 - Conjugation at carbohydrates
25 μΙ_ of antibody solution (i.e BvW) (3.3- 10"9 mol, 5.0- 10"4 g) was diluted with
75 μΙ_ of PBS pH 7.2 and mixed with 10μΙ_ of 0.1 M NalO4 in water (54 eq, 1 .0- 10"6 mol, 2.1 - 10"4 g). The mixture was left to react 2h at 4°C preserved from light. A Nap-5 size exclusion column was used to separate the excess small molecules from the derivatized antibody using phosphate buffer 50 mM pH 6.2. The peptide bearing an aminooxy moiety (60 eq, 2.0- 10"7 mol) was dissolved in 50 μΙ_ of phosphate buffer 25 mM and the pH was made up to 6.2
with 1 M aqueous HCI. The transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 μΙ_ of a 4-10"3 M solution of aniline (60 eq, 2.0- 10"7 mol, 1 .9- 10"5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
Tech 3 - Conjugation through lysines
25 μΙ_ of antibody solution (i.e BvW) (3.3- 10"9 mol, 5.0- 10"4 g) was diluted with 75 μΙ_ of PBS pH 7.2 and incubated with 2-iminothiolane (30 eq, 1 .0- 10"7 mol, 1 .4- 10"5 g) for 1 h at 20°C. A Nap-5 size exclusion column was used to separate the non-reacted 2-iminothiolane from the thiolated antibody using PBS pH 7.2. The peptide bearing a maleimide moiety (10 eq, 3.3- 10"8 mol) was dissolved in 50 μΙ_ of PBS and mixed with the oxidized antibody. The mixture is left to react for 2 h at 20°C. Excess peptide is removed using a Nap-5 size-exclusion column using PBS pH 7.2.
Tech 4. Reduction-Alkylation of interchain antibody disulfides 4.1 Limited disulfide reduction:
4.1 .A. Reduction with DTT:
The antibody solution (i.e. BvW) was diluted (2 mgmL"1, 500 μΙ_) and was partially reduced by DTT (3.25 eq) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C. The excess of DTT was purified away from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following manufacturer instructions). The concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody. 4.1 .B. Reduction with TCEP
The antibody solution (i.e. BvW) was diluted (2 mgmL"1, 500 μί) and was partially reduced by TCEP (2.5 eq respectively) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C. No purification was needed. The concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody.
4.2 Partial reoxidation with DTNB after total reduction with DTT
The antibody solution (i.e.BvW) was diluted (2 mgmL"1, 500 μΙ_) and was totally reduced by DTT (150 eq) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C. The excess of DTT was purified away from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following manufacturer instructions). The fully reduced antibody was cooled to 0 °C and then treated with 2.0 equivalents of DTNB (0°C, 20 min). Without further purification the antibody was alkylated by following the protocol above (alkylation 1 ).
4.3 Alkylation
Partially reduced antibody was alkylated with 1 .1 molar equiv of 5(6)- carboxifluorescein-L-Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp- D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 or rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH2/thiol. The alkylation reaction was performed at 0 °C for 30 min. Cysteine (1 mM final) was used to quench any unreacted, excess of 5(6)-carboxifluorescein-L-Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser- D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 or rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH The excess of peptide was removed from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following
manufacturer instructions).
The antibody concentration was quantified using Nanodrop (coef ext molar = 222714 M"1 cm"1).
Characterization of products:
The identity of the different compounds synthesized with formula I and II (shuttle or combination of shuttle-cargo) was confirmed using mass spectrometry "Matrix Assisted Laser Desorption/lonization-Mass
Spectrometry" (MALDI) (Instrument: MALDI Voyager DE RP time-of-flight (TOF) PE Biosystem) or HPLC-MS (Instrument: Waters model Alliance 2796, quaternary pump, UVA/is detector model 2487, ESI-MS model Micromass ZQ and software Masslynx version 4.0) using a Symmetry 300 d8 (150 x 3.9 mm x 5 μΐη), 300 A column using a 1 mL/min flow; solvents: A: H2O with 0.1 % formic acid; B: MeCN with 0.07 % formic acid. Their purity was checked by reverse phase HPLC using a Symmetry Ci8 column (150 x 4.6 mm x 5 μητι,
100 A, Waters) and a Sunfire Ci8 column (100 x 4.6 mm x 3.5 μηη, 100 A, Waters), flow 1 mL/min; solvents: A: H2O with 0.045% TFA; B: MeCN with 0.036% TFA, Instrument: Waters model Alliance 2695 constituted by a quaternary pump, a diode array detector model 966, controlled by the software Millenium version 3.5.
Constructs including an antibody were characterized by using mass spectrometry "Matrix Assisted Laser Desorption/lonization-Mass
Spectrometry" (MALDI) (Instrument: MALDI Voyager DE RP time-of-flight (TOF) PE Biosystem), SDS page.
SDS-PAGE electrophoresis was carried out using BioRad system
(Miniprotean cell) 7.5 %Tris gel, 25 mM Tris, 192 mM glycine, 0.1 % SDS running buffer). Protein molecular weights were approximated by comparison to a protein marker (Perfect Protein Markers 15-150 kDa from Novagen). Gels were visualised by coomassie staining (staining solution: 10% AcOH, 0.25 g brilliant blue; discoloration solution: 20%MeOH, 3 % AcOH glacial, in water). Edman sequencing (first 4 cycles) was used to quantify the amount of peptides conjugated at the N-termini.
Compounds were purified by HPLC using a Symmetry d8 column (100 x 30 mm x 5 μηη, 100 A, Waters), flow 15 mL/min, solvents: A: H2O with 0.1 % TFA; B: MeCN with 0.1 % TFA, Instrument: Waters system with a quaternary pump, Simple Manager 2700 autoinjector, UVA/is detector model 2487 and a
Fraction collector II, controlled by the software Masslynx version 3.5.
EXAMPLES
Example 1 : Preparation of H-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D- Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 )
The synthesis was performed on a scale 200 μηηοΙ. For the coupling of the first amino acid onto the Fmoc-Rink amide p-MBHA resin the following protocol was used: The protected derivative of the first amino acid (Fmoc-D- Thr(tBu)-OH, 4 eq, 800 pmols, 318 mg) and the coupling agent TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added
sequentially to the resin followed by addition of DIEA (8 eq, 1 .3 mmol, 267 μ
I). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% (v/v) piperidine in DMF (v/v) using two treatments of 1 min and a treatment of 10 minutes.
The protected amino acid derivative of the second amino acid was coupled to the first amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-His(Trt)-OH, 4 eq. 800 mols, 496 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a solution of 20% piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the third amino acid was coupled to the second amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-D-Arg(Pbf)-OH, 4 eq. 800 mols, 519 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the fourth amino acid was coupled to the third amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μί). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed
with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colo metric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 1 0 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to ensure the removal of the Fmoc group.
The protected amino acid derivative of the fifth amino acid was coupled to the fourth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), PyBOP (4 eq, 800 pmols, 41 6 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (1 2 eq, 2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the p-nitro phenyl ester colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 1 0 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 5 min) to ensure the removal of the Fmoc group.
The protected amino acid derivative of the sixth amino acid was coupled to the fifth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Met-OH, 4 eq. 800 mols, 297 mg), PyBOP (4 eq, 800 pmols, 41 6 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (1 2 eq, 2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions.
The extent of coupling was checked using the p-nitro phenyl ester the colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the seventh amino acid was coupled to the sixth amino acid already anchored onto the resin using the following
protocol: the protected amino acid (Fmoc-D-Trp(Boc)-OH, 4 eq. 800 mols, 421 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μΙ_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the eighth amino acid is coupled to the seventh amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Ser(tBu)-OH, 4 eq. 800 mols, 307 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μΙ_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino derivative of the ninth amino acid was coupled to the eighth amino already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to ensure the removal of the Fmoc group.
The protected amino acid derivative of the tenth amino acid was coupled to the ninth amino acid already anchored onto the resin using the following
protocol: the protected amino acid (Fmoc-D-Val-OH, 4 eq. 800 mols, 271 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg), dissolved in DMF (1 -3 ml/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 μΙ_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric assay of p-nitro phenyl ester. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the eleventh amino acid was coupled to the tenth amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Trp(Boc)-OH, 4 eq. 800 mols, 421 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μΙ_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the twelfth amino acid was coupled to the eleventh amino acid already anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to ensure the removal of the Fmoc group.
The cleavage step was performed treating the resin with a mixture of TFA
(94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). tert-butyl methyl ether was added to the product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire d8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Retention time: 5.3 min. Mass spectrometry (MALDI-TOF): [M + H]+: 1489.6; Yield (synthesis and
purification): 8.3%.
Example 2: Preparation of H-Glv-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D- Met-D-Pro-D-Pro-D-Arq-D -His-D-Thr-NH? (SEQ ID NO: 2) The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
For the coupling of the glycine residue to the BBB-shuttle anchored onto the resin the following protocol was used: Fmoc-Gly-OH (4 eq, 800 mols, 238 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HOAt (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling was repeated twice under the same conditions. The extent of coupling was monitored using the p-nitro phenyl ester test. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a treatment of 10 minutes. The cleavage step was performed treating the resin with a mixture of TFA
(94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). tert-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire Ci8 column (100 mm x 4.6
mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 4.3 min. Mass spectrometry (MALDI-TOF): [M + H]+: 1849.3; Yield (synthesis and
purification): 4.7%. Example 3: Preparation of H-Glv-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D- Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-Aminooxv (SEQ ID NO: 2-Aminooxv)
The procedure of the Example 2 was repeated until the coupling of the thirteenth amino acid using Hydroxylamine Novabiotag™ resin with a substitution of 0.56 mmol/g.
The cleavage step was performed treating the resin with a mixture of TFA (95%), H2O (2.5%), and TIS (2.5%) (1 x 2 h). ferf-butyf methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 : 1 ). The product was filtered out and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 1 7 to 23 % MeCN in H2O in 8 minutes using a Sunfire Ci8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 6.4 min. Mass spectrometry (MALDI-TOF): [M + Hf: 1663.9;
Example 4: Preparation of 5(6)-Carboxvfluorescein-L-Lvs(Aminooxy)-D-Pro- D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO:1 for the incorporation of two carqos)
The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid. For the coupling of the Lysine residue to the BBB-shuttle anchored onto the resin the following protocol was used: Fmoc-Lys(Boc -AoA)-OH (4 eq, 800 pmols, 513 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 ,uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric
assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and a treatment of 10 minutes.
For the coupling of the (5)6-carboxyfluorescein to the BBB-shuttle anchored onto the resin the following protocol was used: rhodamine b (4 eq, 800 pmols, 383 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 mols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 μ[_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling was repeated under the same conditions. The extent of coupling was monitored using the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a treatment of 10 minutes.
The cleavage step was performed treating the resin with a mixture of TFA (95%), H2O (2.5%), and TIS (2.5%) (1 x 2 h). Terf-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire C!8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 5.0 min. Mass spectrometry (MALDI-TOF): [M + Hf : 2021 .9;
Example 5: Preparation of Maleimide-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp- D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 with maleimide as
The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
For the coupling of the maleimide to the BBB-shuttle anchored onto the resin the following protocol was used: 6-maleimidohexanoic acid (4 eq, 800 pmols, 169 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin
followed by the addition of 12 eq of DIEA (2.4 mmol, 408 uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay.
The cleavage step was performed treating the resin with a mixture of TFA (95%), H20 (2.5%), and TIS (2.5%) (1 x 2 h). tert-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H20 in 8 minutes using a Sunfire Ci8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 5.3 min. Mass spectrometry (MALDI-TOF): [M + Hf: 2172.7;
Example 6: Preparation of Rhodamine b-L-Lys(Maleimide)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO:1 for the incorporation of two carqos)
The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid. For the coupling of the Lysine residue to the BBB-shuttle anchored onto the resin the following protocol was used: Fmoc-Lys(alloc)-OH (4 eq, 800 pmols, 362 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and a treatment of 10 minutes.
For the coupling of the rhodamine b to the BBB-shuttle anchored onto the resin the following protocol was used: rhodamine b (4 eq, 800 pmols, 383 mg)
in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HOAt (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 1 2 eq of DIEA (2.4 mmol, 408 μ[_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling was repeated under the same conditions. The extent of coupling was monitored using the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a treatment of 10 minutes.
For the deprotection of the Alloc protecting group the following protocol was used: tetrakis(triphenylphosphine)palladium(0) (0.1 eq, 20 prnol, 23 mg) in DCM (1 -3 mL/g resin) and phenylsilane (10 eq, 2.0 mmol, 247 pL) were sequentially added to the resin. The mixture was allowed to react for 15 min. The solvent was removed by suction. The deprotection was repeated two times under the same conditions. The peptidyl-resin is washed with 3 mL of sodium diethyldithiocarbamate 0.02 M.
For the coupling of the maleimide to the BBB-shuttle anchored onto the resin the following protocol was used: 6-maleimidohexanoic acid (4 eq, 800 pmols, 169 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HOAt (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol , 408 ,uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay.
The cleavage step was performed treating the resin with a mixture of TFA (95%), H2O (2.5%), and TIS (2.5%) (1 x 2 h). terf-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 : 1 ). The product was filtered out and lyophilized. Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire Ci8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 4.4 min. Mass
spectrometry (MALDI-TOF): [M + Hf: 1869.1 ;
Example 7: Preparation of 5(6)-Carboxyfluorescein-L-Lvs(Maleimide)-D-Pro- D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D -His-D-Thr-NH? (SEQ ID NO:1 for the incorporation of two carqos)
The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid. For the coupling of the Lysine residue to the BBB-shuttle anchored onto the resin the following protocol was used: Fmoc-Lys(alloc)-OH (4 eq, 800 pmols, 362 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 mols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and a treatment of 10 minutes.
For the coupling of the (5)6-carboxyfluorescein to the BBB-shuttle anchored onto the resin the following protocol was used: rhodamine b (4 eq, 800 pmols, 383 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 ,uL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling was repeated under the same conditions. The extent of coupling was monitored using the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a treatment of 10 minutes.
For the tritylation of the phenol moieties of the carboxylfuorescein the following protocol was used: trityl chloride (12 eq, 2.4 mmol, 223 mg) was added to the resin. The mixture was allowed to react for 16 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The
For the deprotection of the Alloc protecting group the following protocol was used: tetrakis(triphenylphosphine)palladium(0) (0.1 eq, 20 μιτιοΙ, 23 mg) in DCM (1 -3 mL/g resin) and phenylsilane (10 eq, 2.0 mmol, 247 μΙ_) were sequentially added to the resin. The mixture was allowed to react for 15 min. The solvent was removed by suction. The deprotection was repeated two times under the same conditions. The peptidyl-resin is washed with 3 ml_ of sodium diethyldithiocarbamate 0.02 M. For the coupling of the maleimide to the BBB-shuttle anchored onto the resin the following protocol was used: 6-maleimidohexanoic acid (4 eq, 800 pmols, 169 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HO At (12 eq, 2.4 mmol, 327 mg) were sequentially added to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 μΙ_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was monitored using the Kaiser colorimetric assay. The cleavage step was performed treating the resin with a mixture of TFA (95%), H2O (2.5%), and TIS (2.5%) (1 x 2 h). terf-butyl methyl ether was added to the obtained product and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire Ci8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 5.3 min. Mass spectrometry (MALDI-TOF): [M + Hf: 2172.7;
Example 8: Preparation of the compound L-dopa-D-Pro-D-Trp-D-Val-D-Pro- D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 with an L-dopa as cargo or Z group) The procedure of the Example 1 was repeated until the coupling of the twelfth amino acid.
For the coupling the cargo (L-dopa) to the BBB-shuttle anchored onto the resin following protocol was used: the cargo-COOH (Fmoc-L-Dopa-OH) (4 eq, 800 Mmols, 334 mg ) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HOAt (12 eq, 2.4 mmol, 327 mg) were added sequentially to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling was repeated twice under the same conditions. The extent of coupling was monitored using the p-nitro phenyl ester test. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The cleavage step was performed treating the resin with a mixture of TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). Terf-butyl methyl ether and was added to product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire d8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/m in; Retention time: 4.51 min. Mass spectrometry (MALDI-TOF): [M + H]+: 1670.2; Yield (synthesis and purification): 3.8%. Example 9: Preparation of the compound 5(6)-Carboxyfluorescein-D-Pro-D- Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 with 5(6)-Carboxifluorescein as cargo or Z group)
The procedure was repeated as in Example 1 until the coupling of the twelfth amino acid.
For the coupling the cargo (5(6)-carboxyfluorescein to the BBB-shuttle anchored onto the resin following protocol was used: the cargo-COOH (5(6)- carboxyfluorescein) (4 eq, 800 mols, 301 mg) in DMF (1 -3 mL/g resin), PyBOP (4 eq, 800 pmols, 416 mg) and HOAt (12 eq, 2.4 mmol, 327 mg) were added sequentially to the resin followed by the addition of 12 eq of DIEA (2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual
stirring for 1 .5 h. The solvent was removed by suction, the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s).The coupling was repeated twice under the same conditions. The extent of the coupling was monitored using the p- nitro phenyl ester test.
The cleavage step was performed treating the resin with a mixture of TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). tert-butyl methyl ether was added to the obtained product, the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire d8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Retention time: 5.06 min. Mass spectrometry (MALDI-TOF): [M + H]+: 1849.3; Yield (synthesis and purification): 4.2%.
Example 10: Preparation of quantum dot-Glv-D-Pro-D-Trp-D-Val-D-Pro-D- Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq- D-His-D-Thr-NH? (SEQ ID NO: 2 with Quantum dot as cargo or Z group)
The procedure was repeated as in Example 1 until the coupling of the twelfth amino acid. In this example as a spacer between the shuttle and the cargo a molecule of glycine was used. Glycine was added to the shuttle anchored onto the resin using the following protocol: the protected amino acid (Fmoc-Gly-OH, 4 eq. 800 pmols, 190 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric p- nitro phenyl ester assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The cleavage step of the shuttle with the spacer was performed treating the resin with a mixture of TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). Terf-butyl methyl ether was added to the product obtained, the resulting mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet was resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
The coupling of the shuttle equipped with the glycine spacer to the cargo (quantum dot) was performed in solution according to the following protocol: 0.01 mmol (2 mg) of N-(3-dimethylaminopropyl)-N'-etilcarbodimida and 0.025 mmol of N-hydroxysuccinimide (3 mg) were added to 4 mL of a solution of quantum dots (2 mg) in MES (50 mM, pH 6.5), the mixture was allowed to react for 30 minutes. After which 0.08 μ moles (0.12 mg) of the shuttle with spacer of glycine were added. This mixture was allowed to react for 24 h with gentle agitation. The excess peptide and unreacted reagent was removed by dialysis at 4 °C against water for 36 h. The water was changed every 12 hours. Product characterization. The product was characterized by zeta potential measurements at pH 7.4. The product cargo-shuttle zeta displayed a potential of -33.8 mV (the quantum dots none-linked to the shuttle showed a zeta potential of -37.4 mV). Example 1 1 : Preparation of nanoparticle superparamagnetic iron oxide
(SPION)-Glv-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D- Arq-D-His-D-Thr -NH? (SEQ ID NO: 2 with SPION as cargo or Z group).
Example 10 was repeated until the cleavage step of the shuttle with the spacer inclusive.
The binding of the shuttle with a glycine spacer to the superparamagnetic iron oxide nanoparticle in solution was performed according to the following protocol: 0.01 mmol (2 mg) of N-(3-dimethylaminopropyl)-N'-etilcarbodiimide and 0.025 mmoles of N-hydroxysuccinimide (3 mg) were added to 4 mL of a solution of nanoparticles (2 mg) in MES (50 mM, pH 6.5), allowed to react for 30 minutes and added 0.08 μηηοΙ (0.12 mg) of shuttle glycine spacer. It was
allowed to react for 24 h under gentle agitation. Excess peptide and unreacted reagent was removed by dialysis at 4 β C against water for 36 h. The water was changed every 12 hours.
Product characterization. The product was characterized by zeta potential measurements at pH 7.4. The product showed a post-shuttle potential of -31 mV Z (unbound nanoparticles to the shuttle showed a zeta potential of -37.1 mV).
Example 12: Preparation of H-D-Ala-D-NMePhe-D-Nal(21-D-Val-D-Leu-D-Lvs- D-Lvs-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D^Arg-D- His-D-Thr-NH? jSEQ ID NO: 1 with SEQ ID NO: 3 as cargo or Z group)
se<? ib wo r 4 =
The procedure was repeated as in Example 1 until the coupling of the twelfth amino acid.
In this example the cargo was synthesized by solid-phase synthesis directly on the shuttle anchored onto the resin. The first protected amino acid derivative of the cargo was coupled to the BBB-shuttle anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D- Lys(Boc)-OH, 4 eq. 800 pmols, 375 mg), PyBOP (4 eq, 800 umols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1-3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1.5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was repeated twice under the same conditions. The extent of coupling was checked using the colorimetric assay of p-nitro phenyl ester. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a 1 treatment of 10 minutes.
The protected amino acid derivative of the second position of the cargo was coupled over the first amino acid of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Lys(8oc)-OH, 4 eq. 800 mols, 375 mg) and TBTU (4 eq, 800 μπιοΐβ, 257 mg) dissolved in DMF (1-3 mL/g resin) were sequentially added to the resin, subsequently DIEA was added (8 eq, 1.3 mmol, 267 μ L). The mixture was allowed to react with
intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the third position of the cargo was coupled to the second amino acid of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Leu-OH, 4 eq. 800 pmols, 283 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the position fourth of the cargo was coupled to the third amino acid position of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Val-OH, 4 eq. 800 pmols, 271 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the position of the fifth of the cargo was coupled to the fourth amino of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-Nal(2)-OH, 4 eq. 800 pmols, 350 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 mL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and
the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the sixth position of the cargo was coupled to the fifth amino acid of the cargo anchored onto the resin using the following protocol: the protected amino acid (Fmoc-D-NMePhe-OH, 4 eq. 800 pmols, 321 mg) and TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 5 min) to assess the removal of the Fmoc group. The protected amino acid derivative of the position of the seventh of the cargo was coupled to the sixth amino acid of the cargo anchored to the resin using the following protocol: the protected amino acid (Fmoc-D-Ala-OH, 4 eq. 800 pmols, 249 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin was washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the p-nitro phenyl ester colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The cleavage step of the cargo-shuttle construction was performed treating the resin with a mixture of TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). Te/t-butylmethyl ether was added to the product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the
pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized.
Characterization of the cargo-shuttle construction. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire d8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min;
Retention time: 4.52 min. Mass spectrometry (MALDI-TOF): [M + H]+: 2387.3; Yield (synthesis and purification): 9.5%. Example 13: Preparation of H-Glv-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D- Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-Antibodv (SEQ ID NO: 2 with an antibody as cargo or Z group) using tech 1 .
Example 3 was repeated until the cleavage step. The binding of the shuttle with the antibody was done following aminooxy tech 1 , in solution was performed according to the following protocol: 25 μΙ_ of BvW (3.3- 10"9 mol, 5.0- 10"4 g) was diluted with 75 μί of phosphate buffer 25 mM pH 6.5.
Pyridoxal 5'-phosphate (PLP) (298 eq, 1 .0- 10"7 mol, 2.5- 10"5 g) was dissolved in 100 μΙ_ of phosphate buffer 25 mM and the pH was made up to 6.5 with 1 M HCI. The BvW solution was mixed with the PLP solution and incubated at 20 °C for 48 h. A Nap-5 size exclusion column was used to separate the excess small molecules from the derivatized antibody using phosphate buffer 25 mM pH 6.2. The antibody was concentrated to 100 μΙ_ using a Vivaspin 500 with 50 kDa MWCO and washed twice with phosphate buffer 25 mM pH 6.2. The H-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-
His-D-Thr-aminooxy (60 eq, 2.0- 10"7 mol) was dissolved in 50 μΙ_ of phosphate buffer 25 mM and the pH was made up to 6.2 with 1 M aqueous HCI. The transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 μΙ_ of a 4- 10"3 M solution of aniline (60 eq, 2.0- 10"7 mol, 1 .9- 10"5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
The conjugates were characterized by MALDI-TOF MS and the amount of peptide was quantified using 3 cycles of Edman sequencing (1 -2
peptides/Ab).
Example 14: Preparation of H-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D- Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-Antibodv (SEQ ID NO: 2 with an antibody as cargo or Z group) using tech 2 Example 3 was repeated until the cleavage step. The binding of the shuttle with the antibody was done following aminooxy tech 2, in solution was performed according to the following protocol: 25 μΙ_ of BvW (3.3- 10"9 mol, 5.0- 10"4 g) was diluted with 75 μΙ_ of PBS pH 7.2 and mixed with 10μΙ_ of 0.1 M NalO4 in water (54 eq, 1 .0- 10"6 mol, 2.1 - 10"4 g). The mixture was left to react 2h at 4°C preserved from light. A Nap-5 size exclusion column was used to separate the excess small molecules from the derivatized antibody using phosphate buffer 50 mM pH 6.2. H-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D- Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-aminooxy (60 eq, 2.0- 10"7 mol, 3.4- 10"4 g) was dissolved in 50 μΙ_ of phosphate buffer 25 mM and the pH was made up to 6.2 with 1 M aqueous HCI. The transaminated antibody from the Nap-5 column were mixed with the peptide solution and with 50 μΙ_ of a 4-10"3 M solution of aniline (60 eq, 2.0- 10"7 mol, 1 .9- 10"5 g); the mixture was left to react for 48 h. Excess reagents were removed using a Nap-5 size-exclusion column with phosphate buffer 25 mM pH 6.2.
The conjugates were characterized by MALDI-TOF MS (1 -2 peptides/Ab).
Example 15: Preparation of 5(6)-Carboxyfluorescein-L-Lvs(Antibodv)-D-Pro- D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH? (SEQ ID NO: 1 with 5(6)-Carboxifluorescein and an antibody as cargos or Z groups in the compound of formula (ID) using tech 3
Example 7 was repeated until the cleavage step. The binding of the shuttle with the antibody was done following maleimido tech 3, in solution was performed according to the following protocol: 25 μΙ_ of BvW (3.3- 10"9 mol,
5.0- 10"4 g) was diluted with 75 μΙ_ of PBS pH 7.2 and incubated with 2- iminothiolane (30 eq, 1 .0- 10"7 mol, 1 .4- 10"5 g) for 1 h at 20°C. A Nap-5 size exclusion column was used to separate the non-reacted 2-iminothiolane from the thiolated antibody using PBS pH 7.2. carboxyfluorescein-L- Lys(maleimide)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH2 (10 eq, 3.3- 10"8 mol, 7.2- 10"5 g) was dissolved in 50 μΙ_ of PBS and mixed with the oxidized antibody. The mixture is left to react
for 2 h at 20°C. Excess peptide is removed using a Nap-5 size-exclusion column using PBS pH 7.2.
The conjugates are characterized by MALDI-TOF MS and by gel
electrophoresis. (2 peptides/Ab)
Example 16: Preparation of 5(6)-Carboxifluorescein-L-Lvs(Antibodv)-D-Pro- D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 with 5(6)-Carboxifluorescein and an antibody as cargos or Z groups in the compound of formula (ID) using tech 4.1 .A and 4.3.
Example 7 was repeated until the cleavage step. The binding of the shuttle to the antibody was done following maleimido technology tech 4.
An antibody solution (1 mgmL"1, 500 μΙ_) was partially reduced by DTT (3.25 eq, 2.2 μΙ_, 10 mM) or TCEP (2.75 eq, 1 .8 μΙ_, 10 mM) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C. The excess of DTT was purified away from the partially reduced antibody by size exiusion (Nap 5, GE Healthcare following manufacturer instructions). The concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody.
Partially reduced antibody was alkylated with 1 .1 molar equiv of 5(6)- carboxifluorescein-L-Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp- D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2/antibody-cysteine thiol (4eq, 5.8μΙ_, 10 mgmL"1 DMSO) The alkylation reaction was performed at 0 °C for
30 min. Cysteine (1 mM final) was used to quench any unreacted, excess of 5(6)-carboxifluorescein-L-Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D- Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2. The excess of peptide was removed from the partially reduced antibody by size exiusion (Nap 5, GE Healthcare following manufacturer instructions).
The antibody concentration was quantified using Nanodrop (coef ext molar = 222714 M"1 cm"1). Product characterization. The product was characterized by MALDI-TOF. MS: 25827; SDS page and LC MS (1 to 3 peptides/Ab).
Example 17: Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 with Rhodamine b and an antibody as cargos or Z groups in the compound of formula (ID) using tech 3.
Example 6 was repeated until the cleavage step. The binding of the shuttle with the antibody was done following maleimido tech 3, in solution was performed according to the following protocol : 25 μΙ_ of BvW (3.3- 10"9 mol, 5.0- 10"4 g) was diluted with 75 μΙ_ of PBS pH 7.2 and incubated with 2- iminothiolane (30 eq, 1 .0- 10"7 mol, 1 .4- 10"5 g) for 1 h at 20°C. A Nap-5 size exclusion column was used to separate the non-reacted 2-iminothiolane from the thiolated antibody using PBS pH 7.2. rhodamine b-L-Lys(maleimide)-D- Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr- NH2 (10 eq, 3.3- 10"8 mol, 7.4- 10"5 g) was dissolved in 50 μΙ_ of PBS and mixed with the oxidized antibody. The mixture is left to react for 2 h at 20°C. Excess peptide is removed using a Nap-5 size-exclusion column using PBS pH 7.2.
The conjugates are characterized by MALDI-TOF MS and by gel
electrophoresis. (5 peptides/Ab)
Example 18: Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH? (SEQ ID NO: 1 with Rhodamine b and an antibody as cargos or Z groups in the compound of formula (ID) using tech 4.1 .A and 4.3.
Example 6 was repeated until the cleavage step. The binding of the shuttle with the antibody was done following maleimido technology tech 4. An antibody solution (1 mgmL"1, 500 μΙ_) was partially reduced by DTT (3.25 eq, 2.2 μΙ_, 10 mM) or TCEP (2.75 eq, 1 .8 μΙ_, 10 mM) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C. The excess of DTT was purified away from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following manufacturer instructions). The concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.0 to 4.0 thiols/antibody.
Partially reduced antibody was alkylated with 1 .1 molar equiv rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-
D-Arg-D-His-D-Thr-NH2 /antibody-cysteine thiol (4eq, 5.8μΙ_, 10 mgmL
DMSO) The alkylation reaction was performed at 0 °C for 30 min. Cysteine (1 mM final) was used to quench any unreacted, excess of rhodamine b -L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH2. The excess of peptide was removed from the partially reduced antibody by size exclusion (Nap 5, GE Healthcare following manufacturer instructions).
The antibody concentration was quantified using Nanodrop (coef ext molar = 222714 M"1 cm"1).
Product characterization. The product was characterized by MALDI-TOF. MS: 25827; SDS page and LC MS (2 to 3 peptides/Ab).
Example 19: Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arq-D-His-D-Thr-NH? (SEQ ID NO: 1 with Rhodamine b and an antibody as carqos or Z groups in the compound of formula (ID) using tech 4.1 .B and 4.3.
Example 6 was repeated until the cleavage step. The binding of the shuttle with the antibody was done following maleimido technology tech 4. An antibody solution (1 mgmL"1, 500 μί) was partially reduced by TCEP (2.75 eq, 1 .8 il, 10 mM) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 °C. The concentration of antibody-cysteine thiols produced was determined by titrating with DTNB, typically resulting in 3.5 to 4.0
thiols/antibody.
Partially reduced antibody was alkylated with 1 .1 molar equiv rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH2 /antibody-cysteine thiol (4eq, 5.8μί, 10 mgmL"1 DMSO) The alkylation reaction was performed at 0 °C for 30 min. Cysteine (1 mM final) was used to quench any unreacted, excess of rhodamine b -L- Lys(maleimido)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH2. The excess of peptide was removed from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following manufacturer instructions).
The antibody concentration was quantified using Nanodrop (coef ext molar = 222714 M"1 cm*1).
Product characterization. The product was characterized by ALDI-TOF. MS: 150707-155257; SDS page and LC MS (2 to 3 peptides/Ab).
Example 20: Preparation of Rhodamine b-L-Lvs(Antibodv)-D-Pro-D-Trp-D- Val-D-Pro-D-Ser-D-Trp-D-Met-D'Pro-D-Pro-D-Arq-D-His-D-Thr-NHg (SEQ ID NO: 1 with Rhodamine b and an antibody as cargos or Z groups in the compound of formula (II)) using tech 4,2 and 4.3.
Example 6 was repeated until the cleavage step. The binding of the shuttle with the antibody was done following maleimido technology tech 4.
An antibody solution (2.8 mgmL'1, 500 iL) was totally reduced by DTT (150 eq) in 0.025 M sodium borate pH 8, 0.025 M NaCI, 1 mM EDTA for 2 h at 37 "C, The excess of DTT was purified away from the partially reduced antibody by size exclusion (Nap 5, GE Healthcare following manufacturer instructions). The fully reduced antibody was cooled to 0 eC and then treated with 2.0 equivalents of DTNB (1.85 μί, 4mgmL"\ 0°C, 20 min). Without further purification the antibody was alkylated with 1.1 molar equiv rhodamine b-L- Lys(maleimido)-D-Pro-D-Trp-0-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D- Arg-D-His-D-Thr-NH2 /antibody-cysteine thiol (9 eq. 18μί, 10 mgmL"1 DMSO) The alkylation reaction was performed at 0 eC for 30 min. Cysteine (1 mM final) was used to quench any unreacted, excess of rhodamine b -L- l_ys(maleimido)-D-Pro-D-Trp^D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D- Arg-D-His-D-Thr-NH2. The excess of peptide was removed from the partially reduced antibody by size exlusion (Nap 5, GE Healthcare following
manufacturer instructions).
The antibody concentration was quantified using Nanodrop (coef ext molar - 222714 M"1 cm"1).
Product characterization. The product was characterized by MALDI-TOF. MS: 167061.9; SDS page and LC MS (8 peptides/Ab). Comparative Example 1 : Preparation of H-L-Thr-L-His-L-Arq-Pro-L-L-Pro-L- Met-L-Trp-L-Ser-Pro-L-L-Val-L-Tno-L-Pro-NH? (SEQ ID NO|jti
5
The synthesis was performed in a scale 200 μ mol. For the coupling of the first amino acid onto the Fmoc-Rink amide p-MBHA resin the following protocol was used: the first protected amino acid (Fmoc-L -Pro-OH, 4 eq. 800 pmols, 270 mg), TBTU (4 eq, 800 pmols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 microL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to assess the removal of the Fmoc group.
The protected amino acid derivative of the second amino acid was coupled to the first amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Trp(Boc)-OH, 4 eq. 800 mols, 421 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 μί). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric assay of p-nitro phenyl ester. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The third amino acid protected derivative was coupled to the second amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-L-Val-OH, 4 eq, 800 mols, 271 mg) and the coupling agent TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin followed by addition of DIEA (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the fourth amino acid was coupled to the third amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU ( 4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 1 0 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to assess the removal of the Fmoc group. The protected amino acid derivative of the fifth amino acid was coupled to the fourth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Ser(tBu)-OH, 4 eq. 800 mols, 307 mg), PyBOP (4 eq, 800 pmols, 41 6 mg), HOAt (1 2 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (1 2 eq, 2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric p-nitro phenyl ester assay. The Fmoc group was removed with a 20% solution of piperidine in
DMF (v/v) using two 1 min treatments and 1 treatment of 1 0 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 5 min) to assess the removal of the Fmoc group. The protected amino acid derivative of the sixth amino acid was coupled to the fifth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Trp(Boc)-OH, 4 eq. 800 mols, 421 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser
colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes. The protected amino acid derivative of the seventh amino acid was coupled to the sixth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Met-OH, 4 eq. 800 pmols, 297 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μΙ_). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the eighth amino acid is coupled to the seventh amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Pro-OH, 4 eq. 800 mols, 270 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 x 5 min) to assess the removal of the Fmoc group. The protected amino acid derivative of the ninth amino acid was coupled to the eighth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Pro-OH, 4 eq. 800 mols, 270 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling
reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric p-nitro phenyl ester assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes, and treatment with DBU, toluene, piperidine, DMF (5%, 5 %, 20%, 70%) (2 5 min) to assess the removal of the Fmoc group.
The protected amino acid derivative of the tenth amino acid was coupled to the ninth amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Arg (Pbf)-OH, 4 eq. 800 mols, 519 mg), PyBOP (4 eq, 800 pmols, 416 mg), HOAt (12 eq, 2.4 mmol, 327 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (12 eq, 2.4 mmol, 408 microL). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The coupling reaction was carried out twice under the same conditions. The extent of coupling was checked by the colorimetric p-nitro phenyl ester assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The protected amino acid derivative of the eleventh amino acid was coupled to the tenth amino acid already anchored to the resin using the following protocol: the protected amino acid (Fmoc-L-His(Trt)-OH, 4 eq. 800 mols, 496 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments a 1 treatment of 10 minutes.
The protected amino acid derivative of the twelfth amino acid was coupled to the eleventh amino acid anchored onto the resin using the following protocol: the protected amino acid (Fmoc-L-Thr (tBu)-OH, 4 eq. 800 mols, 257 mg), TBTU (4 eq, 800 mols, 257 mg) dissolved in DMF (1 -3 mL/g resin) were
added sequentially to the resin, subsequently DIEA was added (8 eq, 1 .3 mmol, 267 μ L). The mixture was allowed to react with intermittent manual stirring for 1 .5 h. The solvent was removed by suction and the resin washed with DMF (5 x 30 s) and DCM (5 x 30 s). The extent of coupling was checked by the Kaiser colorimetric assay. The Fmoc group was removed with a 20% solution of piperidine in DMF (v/v) using two 1 min treatments and 1 treatment of 10 minutes.
The cleavage step was performed treating the resin with a mixture of TFA (94%), H2O (2.5%), EDT (2.5%) and TIS (1 %) (1 x 1 h). tert-butyl methyl ether was added to the product obtained and the mixture was centrifuged (2 x 8 min). The supernatant was removed and the pellet resuspended in a mixture of H2O and MeCN (1 :1 ). The product was filtered out and lyophilized. Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire d8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Retention time: 4.95 min. Mass spectrometry (MALDI-TOF): [M + H]+: 1489.6; Yield (synthesis and purification): 12%.
Comparative Example 2: Preparation of H-D-Thr-D-His-D-Arq-D-Pro-D-Pro-D- Met-D-Trp-D-Ser-D-Pro-D-Val-D-Trp-D-Pro-NH? (SEQ ID NO: 5)
Comparative Example 1 was repeated but using the corresponding D-amino acids instead of L-amino acids.
Product characterization. Reverse phase HPLC: linear gradient from 0 to 100% MeCN in H2O in 8 minutes using a Sunfire Ci8 column (100 mm x 4.6 mm, 3.5 mm, 100 A, Waters), flow of 1 mL/min; Time retention: 4.3 min. Mass spectrometry (MALDI-TOF): [M + H]+: 1489.6; Yield (synthesis and
purification): 9.8%.
Example 21 : Evaluation of transport across the BBB using an in vitro cell assay
The evaluation method chosen to test the compounds of formula (I) and (II) of the invention was a cell-based assay consisting of a co-culture of brain
endothelial cells and astrocytes, which allows to evaluate or to predict the transport of compounds through the BBB. The co-culture method used was described by Gaillard and de Boer in 2008 (Gaillard, PJ et al. "2B-Trans technology: targeted drug delivery across the blood-brain barrier" Methods Mol Biol 2008, vol. 437 pp. 161 -175) and consists in seeding of rat astrocytes in one side of a polycarbonate filter (transwell) and the seeding of bovine brain endothelial cells on the other side of the filter. Under these conditions endothelial cells are able to reach the confluence mimicking the BBB. The system allows studying the transport of compounds that can cross the BBB by a passive transport mechanism and/or active. Is commonly used model for permeation studies and toxicity of compounds across the BBB.
The co-culture assay was used to determine the capacity of the constructions cargo-shuttle to cross the BBB. The apparent permeability of the compounds was measured in triplicate at a concentration of 50 μ M for Examples 1 , 2, 3, 4 and 7, and at a concentration of 0.75 nM (referred to the particle
concentration) for Examples 5 and 6. All the assays were performed with transendothelial electrical resistance values equal or higher than 125 Ω ■ cm2 and were carried out in the presence of lucifer yellow to assess the integrity of the cell membrane during the test. The permeability tests were performed in Ringer-HEPES buffer at pH 7.4. The compound of interest was dissolved in the buffer to the desired concentration.
Once the endothelial cells were confluent on the filters (transwells) these were washed with Ringer-HEPES buffer. The acceptor well was filled with 800 μ L of Ringer-HEPES buffer and the donor well with 200 μ L of the solution of the compound to be studied. The system was incubated at 37 °C and 5% CO2 for 2 h. After that time the content of the acceptor and donor
compartments were analyzed by HPLC, ICP or fluorescence measurements (depending on cargo anchored to the shuttle). Transport was also confirmed by mass spectrometry MALDI-TOF.
The apparent permeability was calculated using the following equation: Papp = (dQ/dt) * (1 /A) * (1 /CO) (cm/s)
Where (dQ/dt) is the amount of compound present in the compartment
acceptor function of time (nmol/s). A is the area of the filter(cm2) and CO is the initial concentration of the compound applied in the donor compartment (nmol/mL). In Table 2 it can be observed how the use of the shuttle-cargo construct allows that cargos that do not cross themselves are able to do so by means of the BBB-shuttle. Being the shuttle of the example 1 notably more effective than the comparative example 1 with L-amino acids or than the comparative example 2 with D-amino acids. The retroenantio version with D-amino acids has a surprisingly high transport through the blood-brain barrier.
Table 2: Apparent permeability (Papp) and percentage of transport after a 2 hours assay for Examples 1 1 , 2, 8, 9, 10, 1 1 , 12, 15, 16, 17, 18, and 20. As controls the comparative example 1 and 2 are shown. The cargos L-dopa, 5(6)-car boxyfluorescein, rhodamine b, quantum dots, superparamagnetic iron oxide nanoparticles (SPION), the peptide H-D-Ala-D-NMePhe-D-Nal(2)-D- Val-D-Leu-D-Lys-D-Lys-NH2 and antibody Avastin were not detected in the acceptor compartments after the 2 h assay.
considered exceptionally good, and values equal to or higher than 0.1 X10-6 cm/s are considered good. The permeability values depend highly on the cargo used. For a large cargo such as quantum dots or SPION values close to 0.1 X10-6 cm/s and are considered to be very good.
Example 22: Stability of the shuttle in human serum One of the major advantage of the shuttles of this invention is that unlike the vast majority of peptides composed exclusively of L-amino acids (which are rapidly metabolized by a series of enzymes present in the serum of the blood, thus limiting their therapeutic effects), these are made with D-amino acids, thus are not recognized by the metabolic enzymes present in the serum, thereby increasing significantly their half-life in serum.
Regarding to the stability studies in human serum of the BBB-shuttles
(examples 1 and 2) and the peptides presented in the comparative examples 1 and 2, these were incubated at a concentration of 150 μ M in buffer HBSS at 37 °C in the presence of 90% human serum. At a range of times, 50 μΙ_ aliquots were collected to which methanol was added in order to precipitate the serum proteins. The samples were centrifuged, filtered and analysed by HPLC to determine the degree of degradation of the BBB-shuttle In Table 3, it can be observed how the shuttles with D-amino acids show a dramatic increase of its half-life time in human serum, while the version with L-amino acids (Comparative Example 1 ) is rapidly degraded.
In summary, the example 1 and 2 are about shuttle-stable proteases that have a surprisingly high transport through the blood-brain barrier.
Table 3: half-life time of the BBB-shuttle. Comparative Example 1 is shown as control.
Reference Compound Half-life time in compound serum
Comparative H-L-Thr-L-His-L-Arg-L-Pro-L- example 1 Pro-L-Met-L-Trp-L-Ser-L-Pro- < 1 h
L-Val-L-Trp-L-Pro-NH2
Comparative H-D-Thr-D-His-D-Arg-D-Pro-D- example 2 Pro-D-Met-D-Trp-D-Ser-D-Pro- > 24h
D-Val-D-Trp-D-Pro-NH2
Example 1 H-D-Pro-D-Trp-D-Val-D-Pro-D-
Ser-D-Trp-D-Met-D-Pro-D-Pro- > 24h
D-Arg-D-His-D-Thr-NH2
Example 2 H-Gly-D-Pro-D-Trp-D-Val-D-
Pro-D-Ser-D-Trp-D-Met-D-Pro- > 24h
D-Pro-D-Arg-D-His-D-Thr-NH2
Claims
Ri is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from the group consisting of H, CH3C(=O)-, and maleimide;
X is a biradical selected from the group consisting of -NH-(CH2)r-C(=O)-, -C(=O)-(CH2)r-C(=O)-, -S(CH2)r, -S-(CH2)r-C(=O)-, -O-(CH2)r, -S-CH2- CH(NH2)-C(=O)-, -O-(CH2)r-C(=O)-, -(CH2)r-C(=O)-, -NH-O-CH2-C(=O)-NH- (CH2)r-CH(NH2)-C(=O)-, -(CH2)r-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-, and -NH- (CH2)r-CH(NHC(=O)CH2NH2)-C(=O)-; wherein the biradical X is attached to Ri and to the N of the sequence P as follows: Ri -NH-(CH2)r-C(=O)-N(H)m-, R C(=O)-(CH2)r-C(=O)-N(H)m-,
N(H)m-, Rr(CH2)r-C(=O)- N(H)m, R NH-O-CH2-C(=O)-NH-(CH2)r-CH(NH2)- C(=0)- N(H)m, R1-(CH2)r-C(=O)-NH-(CH2)r-CH(NH2)-C(=O)-N(H)mj and R NH- (CH2)r-CH(NHC(=O)CH2NH2)-C(=O)- N(H)m; r is an integer from 1 to 5;
P is a biradical of an amino acid sequence comprising the sequence D-Pro-D- Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1 );
Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is selected from the group consisting of -NH2, -OH, -OR2 and -NHR2;
R2 is a radical selected from the group consisting of (CrC6)-alkyl and (CH2)2- NH-C(=O)-CH2-O-NH2; k is an integer from 0 to 2; m is an integer from 0 to 1 ; with the proviso that when the biradical X is -C(=O)(CH2)rC(=O)-, then is H; with the proviso that when the N of the amino acid of the sequence P to which is attached the biradical X is a biradical -NH-, then m is 1 , and when is a biradical -N-, then m is 0; and
with the proviso that when is maleimide then the biradical X is -C(=0)- (CH2)r-C(=O)-, -CH(NH2)-C(=O)-, -(CH2)r-C(=O)-, and -(CH2)r-C(=O)-NH- (CH2)r-CH(NH2)-C(=O)-.
2. The peptide compound according to claim 1 , wherein:
Ri is the group attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and is selected from the group consisting of H and CH3C(=O)-;
X is a biradical selected from the group consisting of -NH-(CH2)r-C(=O)-, -C(=O)-(CH2)r-C(=O)-, -S(CH2)r, -S-(CH2)r-C(=O)-, -O-(CH2)r, -S-CH2- CH(NH2)-C(=O)- and -O-(CH2)r-C(=O)-; wherein the biradical X is attached to Ri and to the N of the sequence P as follows: Ri -NH-(CH2)r-C(=O)-N(H)m-, RrC(=O)-(CH2)r-C(=O)-N(
N(H)m, and RrO-(CH2)r-C(=O)-N(H)m-; r is an integer from 1 to 3;
P is a biradical of an amino acid sequence comprising the sequence D-Pro-D- Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr (SEQ ID NO: 1 ); Y is the group attached to the C-terminal of the last amino acid of the sequence P, and is selected from the group consisting of -NH2, -OH, -OR2, and -NHR2; R2 is a radical (CrC6)-alkyl; k is an integer from 0 to 2; m is an integer from 0 to 1 ; with the proviso that when the biradical X is -C(=O)(CH2)rC(=O)-, then is H and with the proviso that when the N of the amino acid of the sequence P to which is attached the biradical X is a biradical -NH-, then m is 1 , and when is a biradical -N-, then m is 0.
3. The peptide compound according to any of the claims 1 -2, wherein P is a biradical consisting of SEQ ID NO: 1 .
4. The peptide compound according to any of the claims 1 -2, where P is a biradical that is the sequence Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D- Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr- (SEQ ID NO: 2).
5. The peptide compound according to any of the claims 1 -4, wherein k is an integer from 0 to 1 .
6. The peptide compound according to any of the claims 1 -5, wherein Y is selected from -NH2, -OH and -NHR2.
7. The peptide compound according to claim 6, wherein Y is -NH2.
8. The peptide compound according to any of claims 1 -2, which is selected from the group consisting of:
H-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D- Thr-NH2 (la): and
H-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D- His-D-Thr-NH2 (lb).
X, P, Y, k are as defined in any of the claims 1 -8; q is an integer from 1 to 2, and Z is a radical of a biologically active substance or a substance for use in a diagnostic method, said substance being substantially unable to cross the BBB by itself; wherein when q is 1 , then Z is attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and when q is 2, then one Z is attached to the N-terminal of the first amino acid of the sequence P, optionally via the ligand X, and the other Z is attached to a nitrogen of the biradical X.
10. The construction of formula (II) according to claim 9, which has the formula (II')
Ζ-(Χ)κ-Ρ-Υ (ΙΙ') wherein: X, P, Y, k are as defined in any of the claims 1 -8, q is 1 , and
Z is a radical of a biologically active substance or a substance for use in a diagnostic method, said substance being substantially unable to cross the BBB by itself.
1 1 . The construction according to any of claims 9-10, where P is selected from the group consisting of: a biradical of SEQ ID NO: 2; and a biradical of SEQ ID NO: 1 .
12. The construction according to any of the claims 9-1 1 , wherein k is an integer from 0 to 1 .
13. The construction according to any of the claims 9-12, where Y is -NH2, -OH or -NHR2.
14. The construction according to any of the claims 9-13, wherein Z is a radical of an active pharmaceutical ingredient capable of forming an amide bond, an ester bond, a disulfide bond, a thioeter bond, an oxime bond, an amine bond, or an hydrazone bond with X, and is selected from the group consisting of antiretroviral agents, anticancer agents, antipsychotic agents, antineurodegenerative agents, replacement therapy agents, and antiepileptic agents.
15. The construction according to claim 14, wherein the pharmaceutical active agent is selected from the group consisting of an antibody, L-dopamine and H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys (SEQ ID NO: 3).
16. The construction according to any of the claims 9-13, wherein Z is a radical of a compound selected from the group consisting of an antibody,
5(6)-carboxyfluorescein, Quantum dots, and Spion.
17. The construction according to any of claims 9-10, which is selected from the group consisting of:
L-Dopa-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D- His-D-Thr-NH2 (lla);
H-D-Ala-D-NMePhe-D-Nal(2)-D-Val-D-Leu-D-Lys-D-Lys- D-Pro-D-Trp-D-Val- D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 (Mb);
5(6)-carboxifluorescein-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro- D-Pro-D-Arg-D-His-D-Thr-NH2 (llc); Quantum dot-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro- D-Arg-D-His-D-Thr-NH2 (lid); SPION-Gly-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met-D-Pro-D-Pro-D- Arg-D-His-D-Thr-NH2 (lie),
5(6)-Carboxifluorescein-L-Lys(Antibody)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D- Trp-D-Met-D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 (llf); and
Rhodamine b-L-Lys(Antibody)-D-Pro-D-Trp-D-Val-D-Pro-D-Ser-D-Trp-D-Met- D-Pro-D-Pro-D-Arg-D-His-D-Thr-NH2 (llg).
18. A pharmaceutical composition or a composition for diagnostic purposes comprising a therapeutically effective amount of the construction as defined in any of the claims 9-17, together with appropriate amounts of pharmaceutically acceptable carriers or excipients and/or acceptable for diagnosis.
19. Use of a compound of formula (I) as defined in any of the claims 1 -8, as a shuttle through the blood-brain barrier.
20. The construction of formula (II) as defined in any of the claims 9-15 wherein Z is a radical of a biologically active substance, for use as a medicament.
21 . The construction of formula (II) as defined in any of the claims 9-15, where Z is a radical of dopamine for use in the treatment of Parkinson's disease.
22. The construction of formula (II) as defined in any of the claims 9-15, wherein Z is a peptidic radical of the peptide H-D-Ala-D-NMePhe-D-Nal(2)-D- Val-D-Leu-D-Lys-D-Lys-NH2 (SEQ ID NO: 3) for use in the treatment of Alzheimer's disease.
23. The construction of formula (II) wherein Z is a superparamagentic iron oxide nanoparticle or a gadolinium complex, for use as a contrast agent for a magnetic resonance imaging diagnostic method.
24. The construction of formula (II) wherein Z is selected from a the group consisting of 5(6)-carboxyfluorescein, Texas red, rhodamine and quantum dots, for use as a fluorescent prove for an image diagnostic method.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/379,484 US9475840B2 (en) | 2012-02-27 | 2013-02-27 | Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs |
EP13709338.1A EP2819700B1 (en) | 2012-02-27 | 2013-02-27 | Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs |
ES13709338.1T ES2617853T3 (en) | 2012-02-27 | 2013-02-27 | Protease resistant compounds useful as transporters across the blood brain barrier and transporter-load constructs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230294 | 2012-02-27 | ||
ES201230294 | 2012-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013127829A1 true WO2013127829A1 (en) | 2013-09-06 |
Family
ID=47884249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/053892 WO2013127829A1 (en) | 2012-02-27 | 2013-02-27 | Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs |
Country Status (4)
Country | Link |
---|---|
US (1) | US9475840B2 (en) |
EP (1) | EP2819700B1 (en) |
ES (1) | ES2617853T3 (en) |
WO (1) | WO2013127829A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9254030B2 (en) * | 2009-03-24 | 2016-02-09 | Black Diamond Equipment, Ltd. | Carrying device dual shoulder strap system |
EP3583120B1 (en) | 2017-02-17 | 2022-10-05 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0973804A2 (en) | 1997-04-07 | 2000-01-26 | Genentech, Inc. | Anti-vegf antibodies |
WO2002044329A2 (en) | 2000-11-30 | 2002-06-06 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
WO2007098415A2 (en) | 2006-02-17 | 2007-08-30 | Indiana University Research And Technology Corporation | Peptide based inhibition of capcna protein-protein interactions in cancer |
US20070231300A1 (en) * | 2006-03-28 | 2007-10-04 | Washington, University Of | Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents |
WO2008025867A1 (en) | 2006-09-01 | 2008-03-06 | Universidad De Barcelona | Compounds that act as a vehicle for delivery through the blood-brain barrier and charge delivery vehicle constructions |
WO2008050133A2 (en) | 2006-10-27 | 2008-05-02 | Zapaloid Limited | Inhibition of beta-amyloid aggregation |
WO2009008725A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
WO2011009624A1 (en) * | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
WO2012007625A1 (en) | 2010-07-13 | 2012-01-19 | Universitat De Barcelona | Compounds that can be used as systems for delivery across the blood-brain barrier, and delivery system/load constructs |
-
2013
- 2013-02-27 ES ES13709338.1T patent/ES2617853T3/en active Active
- 2013-02-27 EP EP13709338.1A patent/EP2819700B1/en active Active
- 2013-02-27 US US14/379,484 patent/US9475840B2/en active Active
- 2013-02-27 WO PCT/EP2013/053892 patent/WO2013127829A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0973804A2 (en) | 1997-04-07 | 2000-01-26 | Genentech, Inc. | Anti-vegf antibodies |
WO2002044329A2 (en) | 2000-11-30 | 2002-06-06 | Uab Research Foundation | Receptor-mediated uptake of peptides that bind the human transferrin receptor |
WO2007098415A2 (en) | 2006-02-17 | 2007-08-30 | Indiana University Research And Technology Corporation | Peptide based inhibition of capcna protein-protein interactions in cancer |
US20070231300A1 (en) * | 2006-03-28 | 2007-10-04 | Washington, University Of | Covalent conjugates between endoperoxides and transferrin and lactoferrin receptor-binding agents |
WO2008025867A1 (en) | 2006-09-01 | 2008-03-06 | Universidad De Barcelona | Compounds that act as a vehicle for delivery through the blood-brain barrier and charge delivery vehicle constructions |
WO2008050133A2 (en) | 2006-10-27 | 2008-05-02 | Zapaloid Limited | Inhibition of beta-amyloid aggregation |
WO2009008725A2 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
WO2011009624A1 (en) * | 2009-07-22 | 2011-01-27 | Cenix Bioscience Gmbh | Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes |
WO2012007625A1 (en) | 2010-07-13 | 2012-01-19 | Universitat De Barcelona | Compounds that can be used as systems for delivery across the blood-brain barrier, and delivery system/load constructs |
Non-Patent Citations (7)
Title |
---|
A. MADDER ET AL.: "A novel sensitive colorimetric assay for visual detection of solid-phase bound amines", EUR. J. ORQ. CHEM., 1999, pages 2787 - 2791 |
CARMEN WÃ NGLER ET AL: "In vitro and Initial in vivo Evaluation of Ga-Labeled Transferrin Receptor (TfR) Binding Peptides as Potential Carriers for Enhanced Drug Transport into TfR Expressing Cells", MOLECULAR IMAGING AND BIOLOGY, SPRINGER-VERLAG, NE, vol. 13, no. 2, 15 May 2010 (2010-05-15), pages 332 - 341, XP019888350, ISSN: 1860-2002, DOI: 10.1007/S11307-010-0329-6 * |
E. KAISER ET AL.: "Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides", ANAL. BIOCHEM., vol. 34, 1970, pages 595 - 598 |
GAILLARD, PJ ET AL.: "2B-Trans technology: targeted drug delivery across the blood-brain barrier", METHODS MOL BIOL, vol. 437, 2008, pages 161 - 175 |
J.TEMSAMANI ET AL.: "Improved Brain Uptake and Pharmacological Activity Profile of Morpholine-6-Glucuronide Using a Peptide Vector-Mediated Strategy", J. PHARMACOL. EXP. THER., vol. 313, 2005, pages 712 - 719 |
LEE ET AL., EUR J. BIOCHEM., vol. 268, 2001, pages 2004 - 2012 |
M. AMBLARD ET AL.: "Methods and protocols of modern solid-phase peptide synthesis", MOLECULAR BIOTECHNOLOGY, vol. 33, 2006, pages 239 - 254 |
Also Published As
Publication number | Publication date |
---|---|
US9475840B2 (en) | 2016-10-25 |
EP2819700A1 (en) | 2015-01-07 |
EP2819700B1 (en) | 2016-12-21 |
US20150044140A1 (en) | 2015-02-12 |
ES2617853T3 (en) | 2017-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI240632B (en) | Purified peptides for peptide-based multimeric targeted contrast agents | |
Huang et al. | A novel strategy for surface modification of superparamagnetic iron oxide nanoparticles for lung cancer imaging | |
US20070140974A1 (en) | Targeted nanoparticles for magnetic resonance imaging | |
US20150051153A1 (en) | Environmentally Sensitive Compositions | |
CA2442382A1 (en) | Methods for using annexin for detecting cell death in vivo and treating associated conditions | |
CN102858794A (en) | Peptides whose uptake in cells is controllable | |
EP2819700B1 (en) | Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs | |
US20100267928A1 (en) | Activatable diagnostic and therapeutic compound | |
EP3016671B1 (en) | Actively transported and protease-resistant peptides as bbb shuttles and shuttle-cargo constructs | |
JP5677453B2 (en) | BPB based cargo transport system | |
US10201622B2 (en) | Tumour-targeted theranostic | |
Tian et al. | Glypican-3 (GPC3) targeted Fe 3 O 4 core/Au shell nanocomplex for fluorescence/MRI/photoacoustic imaging-guided tumor photothermal therapy | |
Krauss et al. | Novel daunorubicin‐carrier peptide conjugates derived from human calcitonin segments | |
KR102386477B1 (en) | Novel cell penetrating peptides and use thereof | |
KR102386478B1 (en) | Novel cell penetrating peptides and use thereof | |
KR20070029200A (en) | Peptide-based compounds | |
JPWO2007061036A1 (en) | Contrast media using fullerene derivatives | |
Joshi et al. | Evaluation of crotamine based probes as intracellular targeted contrast agents for magnetic resonance imaging | |
US8008492B2 (en) | Compounds that act as a vehicle for delivery through the blood-brain barrier and charge delivery vehicle constructions | |
US20120034162A1 (en) | Fullerene Assisted Cell Penetrating Peptides | |
CN116217664A (en) | Polypeptide targeting mHSP90, molecular probe and application | |
WO2012007625A1 (en) | Compounds that can be used as systems for delivery across the blood-brain barrier, and delivery system/load constructs | |
Wang | In Vitro Comparative Study of the Binding Affinity and Targeted-drug Delivery Efficiency of EGFR-Targeting Peptides | |
Ulapane | Quantitative Methods to Determine Brain Deposition of Peptides and Proteins after Delivery across the Blood-Brain Barrier | |
KR20230006405A (en) | Novel cell penetrating peptides and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13709338 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14379484 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013709338 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013709338 Country of ref document: EP |